document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis operate segmentbiopharmaceutical additional information business segment item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country percentage revenue significant regioncountry follow year end december dollar millions united states europe japan china total revenue acquisition divestiture continue transform bms leadingedge biopharmaceutical company focus exclusively discover develop deliver innovative medicine address unmet medical need transformation encompass area business operation strategy divest diabete nonpharmaceutical business implement acquisition licensing strategy execute productivity transformation initiative pti divestiture include diabete business february mead johnson december convatec august medical imaging january acquisition licensing strategy acquire ipierian inc ipierian april amylin pharmaceuticals inc amylin august inhibitex inc inhibitex february amira pharmaceuticals inc amira september zymogenetics inc zymogenetics october medarex inc medarex september enter license collaboration arrangement transaction allow continue allow focus resource growth opportunity drive great longterm value disease standpoint focus follow core therapeutic area oncology virology immunology specialty cardiovascular disease fibrosis genetically define disease product pharmaceutical product include chemicallysynthesize drug small molecule increase portion product produce biological process typically involve recombinant dna technology call biologics small molecule drug typically administer orally form pill tablet drug delivery mechanism biologic typically administer patient injection infusion revenue come product follow therapeutic class virology include human immunodeficiency virus hiv infection oncology neuroscience immunoscience cardiovascular pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition business generic competition follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur japan china sell pharmaceutical product country datum provide countrybycountry basis individual country revenue significant outside japan china instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present revenue key product estimate basic exclusivity loss japan china total revenue product past currently estimate year basic exclusivity loss dollar million eua japan china virology baraclude hepatitis franchiseb reyataz sustiva franchise oncology erbitux opdivo sprycel yervoy neuroscience abilify immunoscience orencia cardiovascular eliquis note currently estimate early year basic exclusivity loss include statutory extension exclusivity grant instance able obtain additional month exclusivity product base pediatric extension certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure healthcare law enact qualifying biologic product receive year datum exclusivity biosimilar enter market describe detail intellectual property product exclusivity indicate brand name product trademark own bms specific trademark ownership information include exhibit index currently market product country region indicate uncertainty china exclusivity law result generic competition china market uncertainty china exclusivity law reference include member states european union year end december basic patent application file current member state list product instance date basic exclusivity loss different member states country basic patent obtain datum protection available exclusivity period relate daklinza daclatasvir brand september teva pharmaceuticals launch generic version baraclude entecavir action follow decision june court appeal federal circuit uphold low court decision invalidate baraclude patent february petition rehear banc deny october company file petition writ certiorari supreme court january data exclusivity expire market exclusivity expire exclusivity period relate sustiva efavirenz brand include exclusivity relate combination therapy composition matter patent efavirenz expire method use patent treatment hiv infection expire september pediatric exclusivity grant provide additional month period exclusivity add term patent list orange book october company announce successfully resolve outstanding patent litigation relate efavirenz loss exclusivity efavirenz expect occur december exclusivity period relate sustiva brand include exclusivity relate combination therapy market exclusivity sustiva expire november countries data exclusivity sustiva expire biologic product approve biologics license application bla datum exclusivity expire patent specifically claim composition matter cetuximab active ingredient erbitux right commercialize cetuximab terminate exclusivity period base regulatory datum protection addition anticipate loss exclusivity commercialization right abilify aripiprazole terminate april commercialization rights abilify terminate june summary indication intellectual property position product partner thirdparty manufacturing arrangement product applicable japan baraclude baraclude entecavir potent selective inhibitor hepatitis virus approve food drug administration fda treatment chronic hepatitis virus infection baraclude discover develop internally september teva pharmaceutical launch generic version baraclude entecavir experience rapid significant negative impact net product sale baraclude begin fourth quarter action follow decision june court appeal federal circuit uphold low court decision invalidate baraclude patent february petition rehear banc deny october company file petition writ certiorari request supreme court review january information patent litigation matter item financial statementsnote legal proceeding contingency composition matter patent expire japan uncertainty chinas exclusivity law result generic competition china market bulk active entecavir manufacture company party product finish facility hepatitis franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hepatitis virus infection hcv approve combination medicinal product multiple genotype august dual regimen sunvepra approve japan july currently registrational process patent cover daclatasvir composition matter expire sunvepra asunaprevir asv oral small molecule protease inhibitor treatment hcv approve dual regimen dcvasv japan july october announce pursue fda approval dual regimen withdraw new drug application ndafor asunaprevir manufacture bulk requirement daclatasvir finish product facility obtain bulk requirement asunaprevir thirdparty manufacturer finish product thirdparty facility reyataz franchise reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz franchise include reyataz combination therapy evotaz atazanavir cobicistat oncedaily single tablet drug regiman combine reyataz gilead sciences inc gilead tybost cobicistat treatment hiv infection adult develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net product sale entitle promote reyataz use combination norvir ritonavir non exclusive license agreement abbvie inc abbvie amend royalty pay base percentage net product sale licensing agreement gilead evotaz approve january market exclusivity reyataz expect expire china major member country japan data exclusivity expire manufacture bulk requirement atazanavir finish product facility sustiva franchise sustiva efavirenz nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen combine sustiva gilead truvada emtricitabine tenofovir disoproxil fumarate information arrangement gilead alliance item financial statementsnote alliance right market efavirenz canada france germany ireland italy spain license merck inc merck royalty base percentage revenue efavirenz market company japan composition matter patent efavirenz expire method use patent treatment hiv infection expire september additional month period pediatric exclusivity add term patent october company announce successfully resolve outstanding patent litigation relate efavirenz loss exclusivity efavirenz expect occur december market exclusivity sustiva expire november countries data exclusivity sustiva expire obtain bulk requirement efavirenz party produce finished good facility supply party bulk efavirenz gilead responsible produce finished atripla product erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve combination irinotecan treatment patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail fda approve erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbase chemotherapy fluorouracil exclusive distribution right north america cetuxmab grant company imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly alliance lilly information alliance lilly alliance item financial statementsnote alliance data exclusivity erbitux expire patent specifically claim composition matter cetuximab active molecule erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination fluorouracil antineoplastic agent approve fda combination use claim grant patent expire include grant patent term extension use patent challenge yeda research development company ltd yeda pursuant december worldwide settlement agreement sanofi yeda grant imclone nonexclusive worldwide license use patent datum exclusivity japan expire yeda right license use patent party grant amgen inc amgen license amgen receive fda approval market egfrproduct compete erbitux yedas license patent party result product competition erbitux occur unable assess potential impact competition obtain finish good requirement cetuximab use north america lilly lilly manufacture bulk requirement cetuximab facility fill finish perform party bms oversight responsibility description supply agreement lilly manufacture quality assurance opdivo opdivo nivolumab fully human monoclonal antibody bind program death receptor nkt cell investigate anticancer treatment phase iii trial commence nonsmall cell lung cancer renal cell cancer melanoma jointly patent ono pharmaceutical ltd ono cover opdivo composition matter expire exclude potential patent term extension december fda approve opdivo unresectable inoperable metastatic melanoma disease progression follow yervoy braf mutation positive braf inhibitor opdivo approve japan july indication fda grant fast track designation opdivo tumor type non small cell lung cancer renal cell carcinoma metastatic melanoma registrational process melanoma nonsmall cell lung cancer europe fda grant breakthrough therapy designation hodgkin lymphoma obtain bulk requirement opdivo party finish product facility sprycel sprycel dasatinib multitargete tyrosine kinase inhibitor approve firstline treatment adult philadelphia chromosome positive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate gleevec trademark novartis sprycel internally discover alliance otsuka information alliance otsuka pharmaceutical ltd otsuka alliance item financial statementsnote alliance patent term extension grant extend term basic composition matter patent cover dasatinib june company enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate abbreviate new drug application anda product september early certain circumstance orphan drug exclusivity expired protect product generic application currently approve orphan indication majority country composition matter patent cover dasatinib expire april exclude potential term extension composition matter patent expire japan china manufacture bulk requirement dasatinib finish product facility yervoy yervoy ipilimumab biological product monoclonal antibody treatment patient unresectable metastatic melanoma yervoy approve march july currently study indication include lung cancer adjuvant melanoma hormonerefractory prostate cancer information research development yervoy research development yervoy discover medarex codevelope company medarex subsidiary patent cover ipilimumab composition matter currently expire exclude potential patent term extension datum exclusivity expire bulk ipilimumab manufacture company party product finish facility party facility abilify abilify aripiprazole atypical antipsychotic agent adult patient schizophrenia bipolar mania disorder major depressive disorder abilify pediatric use schizophrenia bipolar disorder global commercialization agreement otsuka exclude japan china certain asian country information arrangement otsuka alliance item financial statementsnote alliance basic composition matter patent cover aripiprazole term current abilify agreement expire april include grant patent term extension month pediatric extension composition matter patent force major country original expiration date extend grant supplementary protection certificate country data exclusivity right commercialize expire june obtain bulk requirement aripiprazole otsuka company otsuka finish product facility orencia orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderately severely active rheumatoid arthritis inadequate response certain currently available treatment orencia available intravenous subcutaneous formulation europe japan series patent cover abatacept method use patent term extension grant composition matter patent extend term patent composition matter patent covering abatacept expire majority country apply supplementary protection certificate pediatric extension supplementary protection certificate protection protection certificate grant datum exclusivity expire japan bulk abatacept manufacture company party finish formulation product facility alliance discussion collaboration ono orencia japan eliquis eliquis apixaban oral factor inhibitor target stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorder apixaban discover internally alliance pfizer inc pfizer information alliance pfizer item financial statementsnote alliance composition matter patent cover apixaban expire february exclude potential patent term extension expire apply supplementary protection certificate supplementary protection certificate grant expire datum exclusivity expire apixaban manufacture company party product finish facility research development invest heavily research development believe critical longterm competitiveness major facility new jersey connecticut research development carry facility world include belgium india site supplement internal drug discovery development program alliance collaborative agreement help bring new product pipeline drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product management continue emphasize leadership innovation productivity quality strategy success research development activity concentrate research development effort follow disease area significant unmet medical need immunooncology oncology immunoscience cardiovascular virology fibrotic disease genetically define disease continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug include phase phase phase iii clinical trial design specifically support new drug application particular indication assume trial successful phase clinical trial involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase clinical trial involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical trial conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate process typically take fourteen year long approximately year spend phase iii latestage development consider program phase iii significant program program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation drug development time consume expensive risky average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval failure rate compound enter phase development approximately compound enter phase iii development approximately total research development expense include cost discovery research preclinical development early latestage clinical development drug formulation postcommercialization medical support market product proportionate allocation enterprisewide cost appropriate cost research development spend billion billion billion include payment thirdparty collaboration contract end employ approximately people activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage program portfolio basis invest resource stage research development early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense year individual investigational compound market product represent expense year list latestage investigational compound phase iii clinical trial regulatory review potential indication investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound patent coverage highlight include patent term patent term extension grant beclabuvir beclabuvir oral small molecule nonnucleoside nsb inhibitor phase iii development commence treatment hcv patent cover beclabuvir composition matter expire elotuzumab elotuzumab humanized monoclonal antibody investigate anticancer treatment discover pdl biopharma alliance abbvie phase iii trial commence multiple myeloma fda grant breakthrough therapy designation elotuzumab use combination lenalidomide dexamethasone treatment multiple myeloma patient receive prior therapy abbvie own patent cover elotuzumab composition matter expire bms bms investigational compound study hiv show antiviral activity hiv infect individual attachment inhibitor distinct mode action entry inhibitor prevent entry hiv host cell follow attachment bms prodrug metabolize active basic compound hold patent cover bms composition matter expire november terminate phase iii development peginterferon lambda treatment hepatitis virus follow table list potential additional indication andor formulation key marketed product potentially registrational trial currently regulatory review key market product potential indication andor formulation hepatitis franchise combination antiviral treatment hcv reyataz pediatric extension opdivo additional indication melanoma nonsmall cell lung cancer hematology renal cell carcinoma head neck cancer additional indication melanoma renal cell carcinoma glioblastoma combination yervoy yervoy additional indication adjuvant melanoma prostate cancer nonsmallcell lung cancer small cell lung cancer additional indication melanoma renal cell carcinoma glioblastoma combination opdivo orencia additional indication lupus nephritis psoriatic arthritis autoinjector device follow key development currently expect occur respect significant pipeline program outcome timing expect development dependent number factor include thing availability datum outcome certain clinical trial acceptance presentation certain medical meeting andor action health authority undertake obligation publicly update information result new information future event hepatitis franchise datum available clinical trial potential approval daclatasvir opdivo potential approval lung cancer potential approval melanoma data available clinical trial include datum phase iii study lung cancer potential submission tumor base registrational trial yervoy potential approval adjuvant melanoma datum available phase iii study prostate lung cancer potential submission tumor base registrational trial elotuzumab datum available phase iii study multiple myeloma alliance enter alliance party transfer right develop manufacture market andor sell pharmaceutical product own party alliance include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance involve share research development cost risk incur research development expense compound lead revenuegenerate product reduce profitability alliance product generally low profit alliance product share alliance partner actively pursue arrangement view alliance important complement discovery development commercialization activity alliance party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure number alliance agreement permit alliance partner terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance short notice general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant alliance material result operation cash flow material financial condition liquidity customary pharmaceutical industry term alliance generally coextensive exclusivity period vary countrybycountry basis significant current alliance currently market product investigational compound describe current market productsinlicense otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement exclude certain asian country portion agreement amend expire expect loss product exclusivity april agreement expire european union countries june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country detailed description share revenue expense abilify item financial statement note alliance portion abilify agreement oncology agreement describe include changeofcontrol provision acquire acquire company compete product abilify new company assume abilify agreement amend oncology agreement currently exist acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right abilify agreement amend price accord predetermine schedule agreement provide event generic competitor abilify option terminate abilify april amendment agreement previously amend remain force exercise option receive payment otsuka accord pre determine schedule oncology agreement terminate time oncology agreement continue truncated period accord predetermine schedule early termination abilify agreement immediate notice case voluntary bankruptcy minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event challenge otsuka patent right marketbymarket basis event market product direct competition abilify termination expiration abilify agreement retain right abilify discussion oncology agreement otsuka current market productsinternally discover discussion alliance otsuka item financial statementsnote alliance gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility certain activity relate commercialization atripla canada certain european country gilead recognize atripla revenue canada countries europe alliance revenue recognize atripla include bulk efavirenz component atripla calculate differently follow loss exclusivity sustiva alliance revenues defer related alliance receivable recognize atripla sell thirdparty customer collaboration agreement govern commercialization atripla canada continue terminate mutual agreement party describe event material breach party collaboration agreement nonbreache party terminate agreement breach party cure material breach party agree desirable practicable withdraw combination product market commercialize time generic version party component product launch party right terminate collaboration agreement control joint venture commercialization combination product canada year terminate party continue receive percentage net product sale base contribution bulk component atripla retain right product europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expiration occur atripla truvada sustiva enter licensing agreement gilead develop commercialize fixeddose combination contain reyataz gileads cobicistat pharmacoenhance boost agent increase blood level certain hiv medicine potentially allow pill daily dose april company file new drug application nda fda combination treatment evotaz atazanavir cobicistat approve fda january discussion alliance gilead item financial statementsnote alliance lilly egfr commercialization agreement lilly lillys subsidiary imclone codevelopment copromotion erbitux canada japan egfr agreement respect erbitux net product sale north america lilly receive distribution fee base flat rate net product sale north america plus reimbursement certain royalty pay lilly company lilly share half profit loss evenly japan merck kgaa receive half profit loss japan party share royalty payable party pursuant formula set forth commercialization agreement purchase north american commercial requirement bulk erbitux lilly agreement expire erbitux north america september early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance retain rights erbitux north america share codevelopment copromotion right erbitux merck kgaa japan agreement sign october lilly merck kgaa merck japan erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer head neck cancer december december bms agree transfer cocommercialization right japan merck kgaa exchange future royalty include income earn discussion alliance lilly item financial statementsnote alliance current market productsinternally discover otsuka simultaneously extension abilify agreement april company otsuka enter oncology agreement sprycel ixempra ixabepilone include japan market oncology territory beginning fee pay otsuka annually base percentage annual net product sale sprycel ixempra oncology agreement expire respect sprycel ixempra include changeofcontrol provision acquire abilify agreement describe discussion abilify agreement otsuka current market productsinlicense discussion alliance otsuka item financial statementsnote alliance addition january grant otsuka exclusive right japan develop commercialize onglyza agreement entitle receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan june otsuka assign right onglyza exception specific transition service kyowa hakko kirin khk consent assignment bms waive right copromote onglyza japan february sell astrazeneca diabete business comprise global alliance include right ownership onglyza seeitem financial statementsnote alliance discussion astrazeneca january enter worldwide japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement farxiga sglt agreement bms astrazeneca pharmaceutical whollyowne subsidiary astrazeneca enter alliance worldwide development commercialization amylin portfolio product include bydureon byetta symlin kombiglyze codevelope astrazeneca saxagliptin agreement exclusive right develop sell onglyza japan license otsuka december june assign otsuka khk describe february sell astrazeneca diabete business comprise global alliance include right ownership onglyza farxiga bydureon byetta symlin myalept astrazeneca terminate exist alliance agreement connection sale enter new agreement include transitional service agreement supply agreement development agreement supply agreement continue manufacture onglyza kombiglyze farxiga discussion alliance astrazeneca item financial statementsnote alliance investigational compound development internally discover pfizer company pfizer party worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover prevention treatment atrial fibrillation vte disorder pfizer fund development cost depend study company share commercialization expense profit loss equally global basis discussion alliance pfizer item financial statementsnote alliance ono bms ono alliance agreement develop commercialize opdivo antipd human monoclonal antibody investigate anticancer treatment bms exclusive right develop manufacture commercialize opdivo territory worldwide japan south korea taiwan ono responsible development commercialization prior amendment discuss ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate north america applicable territory alliance agreement amend july provide additional collaboration activity japan south korea taiwan pertain opdivo bms compound include ipilimumab lirilumab urelumab bms antilag party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer alliance bms reckitt benckiser group plc reckitt enter year alliance overthecounterproduct sell primarily mexico brazil reckitt receive right sell distribute market product certain responsibility relate regulatory matter cover territory bms receive royalty net product sale exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include market authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine base multiple sale plus cost remain inventory hold bms time april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance option exercise substantially employee facility expect transfer reckitt option exercise option exercise asset previously transfer reckitt revert bms option exercise reckitt november case closing expect occur february bms medicine company enter year alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc medicine company receive right sell distribute market recothrom global basis year certain responsibility relate regulatory matter cover territory bm exclusively supply recothrom medicine company pursuant supply agreement cost plus markup receive royalty net product sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include recothrom bla relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option acquire business million february item financial statementsnote alliance information alliance investigational compound developmentinlicense abbvie august grant exclusive right pdl biopharma inc abbvie elotuzumab humanize monoclonal antibody investigate treatment multiple myeloma term collaboration fund development cost elotuzumab commercialization abbvie share profit loss pay tiere royalty outside solely responsible commercialization elotuzumab addition abbvie receive milestone payment base certain regulatory event sale threshold achieve licensing arrangement addition alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz merck efavirenz certain compound outlicense party development commercialization include obtain acquisition entitle receive milestone payment compound regulatory process royalty base net product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example japan certain country regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term japan china provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection region china questionable datum protection law enforceable certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file nda medicine biological product biologic license application bla file type application file affect regulatory exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical trial receive year datum protection formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluates maa provide recommendation european commission approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity china china medicines new chemical entity generally afford year datum exclusivity approve indication dosage uncertainty china exclusivity law result generic competition china market generic copy receive regulatory approval datum exclusivity patent expiration currently unlike china patent term restoration compensate patent term lose regulatory process general chinese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan china wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote appropriate use product directly healthcare professional provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical government regulation price constraint field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information product provide information response unsolicite inquiry doctor medical professional manage care organization operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new product new use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation cardinal health inc amerisourcebergen corporation business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler distributor maintain inventory level month demand ima include large wholesaler expire december company negotiate extension ima large wholesaler march continue discussion certain wholesaler customer extend renew agreement period current expiration number define country outside establish scale distributor model medically necessary drug available patient continue marketing authorization trademark product contract service fullservice distributor provide distribution logistic regulatory pharmacovigilance sale advertising promotion certain product contract clearly define term condition service provide supply firm order period monitor incountry sale forecast ensure reasonable inventory level product sale maintain fully continuously meet demand product distributor territory responsibility sale distributorbase country represent approximately company total revenue competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service research development new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion revenue product short period time rate revenue decline product expiration exclusivity vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential different national pricing reimbursement law lead significant parallel trade flow healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase march government enact healthcare reform legislation sign law patient protection affordable care act reconciliation bill contain package change healthcare bill legislation make extensive change current system healthcare insurance benefit intend broaden coverage reduce cost bill significantly change americans receive healthcare coverage pay significant impact company particular company pharmaceutical industry healthcare relate industry include bms experience continue experience additional financial cost certain change business new healthcare law implement example minimum rebate medicaid drug sale increase percent percent medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion drug pricing program public health service act begin require provide percent discount brandname drug patient fall medicare coverage gap refer donut hole require pay annual nontaxdeductible fee federal government base allocation market share brand prior year sale certain government program include medicare medicaid department veterans affairs department defense tricare discussion rebate program item management discussion analysis financial condition result operationstotal revenue critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing government regulation price constraint pharmaceutical manufacturing facility locate puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multiproduct bulk biologic manufacturing facility deven massachusetts continue capital investment facility announce plan build new largescale biologic manufacturing facility cruiserath ireland rely party manufacture supply portion active ingredient necessary manufacture product include baraclude sustiva franchise erbitux yervoy reyataz abilify orencia eliquis begin february follow sale diabete business astrazeneca astrazeneca assume manufacturing responsibility bydureon byetta maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely capacity devens massachusetts facility capacity available thirdparty contract manufacturer manufacture orencia thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet complex processing requirement biologic business performance prospect negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million million capital project undertake specifically meet environmental requirement addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee december employ approximately people foreign operation significant operation outside conduct subsidiary distributor geographic breakdown total revenue table caption geographic area item financial statementsnote business segment information discussion total revenue geographic area item management discussion analysis financial condition result operationstotal revenue international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net unfavorable impact growth rate revenue predict certainty future change foreign exchange rate effect growth rate revenue attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument fair value measurement bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption addition information sustainability program available website responsibility caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation financial condition face intense competition manufacturer include innovative medicine lowerprice generic product bms dependent uptake market expansion market brand new product introduction new indication product extension copromotional activity alliance partner deliver future growth competition major global challenge include lowerprice generic increasingly aggressive generic commercialization tactic low price company product real perceive superior efficacy benefit safety risk profile differentiate factor iii technological advance patent attain competitor clinical study result product competitor product affect value proposition product business combination competitor major customer compete interest external partnership develop bring new product market experience limited block market access real perceive difference value proposition product compare competitor lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file market addition patent environment unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version approve market generic biosimilar product manufacturer increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject patent litigation case manufacturer seek regulatory approval submit clinical trial datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation example experience rapid significant negative impact baraclude net product sale fourth quarter launch generic entecavir follow federal court decision invalidate composition matter patent february assurance particular product enjoy market exclusivity time period appear estimate disclose addition country india allow competitor manufacture sell compete generic product know compulsory licensing negatively impact protection afford company lowerprice biosimilar bms biologic product compete biologic introduce new competition key product potentially impact volume price increase pricing pressure restriction abroad manage care organization institutional purchaser government agency program negatively affect revenue profit margin product continue subject increase pressure portfolio market access pricing rebate restriction region world include rule practice manage care organization institutional governmental purchasers judicial decision governmental law regulation medicare medicaid healthcare reform include patient protection affordable care act iii potential impact pharmaceutical reimbursement medicare formularie product pricing general delay gain reimbursement government price erosion mechanism europe country result deflation pharmaceutical product pricing collection delay governmentfunde public hospital outside vii impact pricing parallel trade border viii development technology andor industry practice impact reimbursement policy practice thirdparty payer limited block market access real perceive difference value proposition product compare compete product experience difficulty delay development commercialization new product compound product appear promise development fail reach market expected optimal timeframe addition product extension additional indication approve develop commercialize new compound product include inherent risk uncertainty include efficacy safety concern delay deny regulatory approval delay challenge produce product commercial scale excessive cost manufacture failure enter implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product failure product achieve maintain commercial viability change regulatory approval process cause delay denial new product approval regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program include inprocess research development iprd cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent increase percentage pretax income include royalty relate sanofi alliance outlicense intellectual property contingent proceed result divestiture diabete business pretax income generate royalty approximately million pretax income adversely affect royalty stream decline future period failure execute business strategy adversely impact growth profitability able consistently maintain rich pipeline internal program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction able successfully realize expect efficiency effectiveness change structure operation diversify specialty biopharmaceutical strategy unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change transformational issue manage cost effectively operate result financial condition negatively impact failure attract retain highly qualified personnel affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel cost materially increase public announcement datum clinical study news development relate latestage immunooncology compound likely cause significant volatility stock price development key immunooncology compound combination therapy delay discontinued stock price decline significantly focus effort resource certain disease area focus portfolio investor place heighten scrutiny late stage compound particular opdivo important asset immunooncology portfolio announce multiple regulatory milestone opdivo fully human monoclonal antibody investigate anticancer treatment nonsmalllung cancer renal cell cancer melanoma tumor type combination approve cancer product yervoy expect receive news ongoing clinical trial health authority announcement datum clinical study news development relate latestage immunooncology compound nivolumab likely cause significant volatility stock price furthermore announcement negative unexpected datum discontinuation development key immunooncology compound combination therapy delay anticipate timeline file regulatory approval likely cause stock price decline significantly assurance datum clinical study support file regulatory approval approve key immunooncology compound commercially successful business acquire future underperform able successfully integrate exist business continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control substantial difficulty cost delay result integrate acquisition include manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii company culture compensation structure human resource activity tax consideration depend key product revenue cash flow earning historically derive majority revenue earning key product heavily dependent product past year dependence profitability product likely continue instance abilify revenue billion represent revenue orencia sprycel revenue total billion billion represent revenue respectively lose right abilify international market april expect growth product yervoy eliquis opdivo increase important revenue base reduction revenue product significantly negatively impact revenue cash flow earning change foreign law regulation negatively affect revenue profit margin subject new government law regulation negatively affect business operating result financial condition company additional healthcare reform initiative country include additional mandatory discount fee increase tax revenue country mean reduce debt change tax rate limit phasingout eliminate deduction tax credit modify tax collection process tax certain tax haven tax certain excess income intellectual property change rule earning repatriation change tax law iii new law regulation judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction change intellectual property law change accounting standard increase datum privacy regulation enforcement vii emerge new global regulatory requirement report payment value transfer healthcare professional viii potential impact importation restriction legislative andor regulatory change product labeling change market product result negative impact revenue regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead trial adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution manage care organization scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead trial affect product formulary listing adversely affect revenue experience difficulty delay manufacture distribution sale product product supply relate patient access negatively impact thing product seizure recall force closing manufacture plant disruption supply chain continuity include natural manmade disaster facility critical supplier failure failure supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure sole source single source supplier provide necessary raw material supply finish good reasonable timeframe failure thirdparty manufacturer supply bulk active finished product time construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation business interruption adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act antibribery act recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law viii environmental health safety sustainability matter tax liability depend party meet contractual regulatory obligation rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance information technology business unit functional service meet contractual regulatory obligation party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact company operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence increasingly dependent information technology system infrastructure face certain risk include cyber security datum leakage significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store system nonencrypte portable medium storage device experience business interruption information theft confidential information reputational damage industrial espionage attack malware cyber attack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue invest industry appropriate protection monitor practice datum information technology reduce risk continue monitor system ongoing basis current potential threat assurance effort prevent breakdown breach thirdparty provider database system adversely affect business social medium platform present risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce external medium channel lead information loss structured process place secure protect information identify new point entry social medium continue expand present new challenge adverse change global regional local economic condition adversely affect profitability global economic risk pose significant challenge company growth profitability difficult mitigate world major economy hold historicallyhigh debt level experience slow growth high unemployment rate risk lie ahead include management debt european sovereign debt significant operation europe include manufacturing exposure customer credit risk europe include governmentguaranteed hospital receivables market payment receive time addition future pension plan funding requirement continue sensitive global economic condition relate impact equity market expose commercial risk economic factor control pose significant challenge underlie profitability change foreign currency exchange interest tax rate material adverse effect operating result liquidity significant operation outside generate approximately revenue revenue earning cash flow expose risk strengthen dollar euro japanese yen chinese renminbi canadian dollar south korean difficult mitigate example february dollar strengthen euro approximately japanese yen approximately compare average rate derivative financial instrument hedge certain underlying economic exposure financial instrument include derivative subject counterparty credit risk addition result operation negatively impact member country exit expose change interest rate ability access money market andor capital market impede adverse liquidity market condition occur debt rating pressure financial clinical expectation meet illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand addition theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business item unresolved staff comment item property world headquarter locate park avenue new york lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe rest world total portion manufacturing location property own lease research development administration storage distribution information property item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item safety disclosure applicable executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year lamberto andreotti president chief operating officer director company chief executive officer director present chief executive officer director company member senior management team charle bancroft chief financial officer company executive vice president chief financial officer present executive vice president chief financial officer company member senior management team giovanni caforio senior vice president oncology global commercialization chief operating officer director senior vice president oncology immunology global commercialization member senior management team president pharmaceuticals executive vice president chief commercial officer present chief operating officer director company joseph caldarella vice president corporate controller senior vice president corporate controller present senior vice president corporate controller francis cuss bchir frcp senior vice president discovery exploratory clinical research executive vice president chief scientific officer senior vice president research member senior management team present executive vice president chief scientific officer john elicker vice president investor relation senior vice president public affairs investor senior vice president investor relation relation present senior vice president public affairs investor relation member senior management team ann powell judge chief human resource officer shire pharmaceutical senior vice president global human resource present senior vice president global human resource member senior management team sandra leung general counsel corporate secretary executive vice president general counsel present executive vice president general counsel corporate secretary corporate secretary member senior management team samuel moe senior vice president worldwide strategy operation senior vice president strategic plan senior vice president strategy analysis present senior vice president strategic planning analysis member senior management team anne nielsen vice president associate general counsel senior vice president chief compliance senior vice president deputy general counsel ethic officer present senior vice president chief compliance ethic officer member senior management team louis schmukler senior vice president specialtybiotechnology operating unit pfizer president global manufacturing supply present president global manufacturing supply member senior management team paul von autenrie vice president chief information officer senior vice president enterprise service chief senior vice president chief information officer information officer present senior vice president enterprise service chief information officer member senior management team item market registrant common stock stockholder matter market price bristolmyer squibb common stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present high low high low common quarter second quarter quarter fourth quarter holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow quarterly dividend share pay period indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february unregistere sale equity security use proceed follow table summarize surrender equity security month period end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea plan programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december reflect share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program board director authorize repurchase billion common stock june board director increase authorization repurchase common stock additional billion repurchase program expiration date consider future repurchase item select financial datum year financial summary amount million share datum income statement dataa total revenue continue operation net earning net earning attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtc equity discussion item affect comparability result year item management discussion analysis financial condition result operationsnongaap financial measure include current noncurrent marketable security include current portion longterm debt item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease continue evolve business lead diversified specialty biopharma company evolution accelerate result diabete business divestiture continue focus certain therapeutic area include immunooncology follow provide brief summary certain key event discuss detail report opdivo approve japan unresectable metastatic melanoma announce positive result certain study melanoma lung hodgkin lymphoma renal cell carcinoma clinical collaboration enter seek opportunity strategically combine opdivo target agent dozen tumor type eliquis obtain important label extension receive regulatory approval hepatitis franchise include daklinza dual regimen daklinza sunvepra japan business development transaction complete advance pipeline therapeutic area include fibrosis genetically define disease expand biologic manufacturing capacity deven massachusetts announce plan build new facility ireland revenue decrease result diabete business divestiture exclusivity loss expiration right partially offset high sale key product include recently launch product certain market focus optimize global brand key market accelerate growth key product eliquis sale increase million follow global launch yervoy sale increase million continue penetration communitybase set line indication improve access internationally hepatitis franchise sale million follow launch japan certain country expect product continue grow orencia sprycel recently launch opdivo partially offset revenue reduction result expiration certain right pertain abilify royalty alliance agreement exclusivity loss baraclude change foreign currency rate high pension research development relate charge contribute reduction gaap eps nongaap ep increase proceed diabetes divestiture increase cash marketable security billion highlight follow table summarize financial information year end december dollar million share datum total revenue total expense earning income taxis provision forbenefit income taxis effective taxbenefit rate net earning attributable bms gaap nongaap dilute earning share gaap nongaap cash cash equivalent marketable security nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure nongaap financial measure strategy continue transform bms lead diversified specialty biopharma company focus exclusively discover develop deliver innovative medicine address unmet medical need continue evolve drive fundamental objective grow market product progress pipeline develop new medicine follow core therapeutic area oncology virology immunooncology specialty cardiovascular disease fibrosis genetically define disease pioneer innovative medicine area immunooncology unlock bodys immune system battle cancer yervoy ipilimumab immunooncology agent introduce treatment metastatic melanoma announce multiple regulatory milestone european union opdivo nivolumab investigational immune checkpoint inhibitor continue invest significantly deep pipeline innovative medicine cover broad array cancer enter collaboration agreement research develop opdivo approve investigational oncology agent combination regiment evolve commercial model grow market product portfolio manner consistent overall strategy oncology building success yervoy yield revenue approximately billion product sprycel dasatinib erbitux cetuximab oncology remain strongly commit eliquis apixaban launch globally alliance pfizer inc pfizer eliquis receive regulatory approval treatment deep vein thrombosis dvt pulmonary embolism adult related indication continue support key brand virology franchise reyataz atazanavir sulfate baraclude entecavir achieve regulatory milestone hepatitis portfolio launch daklinza daclatasvir sunvepra asunaprevir dual regimen japan launch daklinza addition continue invest orencia abatacept account approximately billion revenue look ahead continue implement biopharma strategy drive growth key brand execute new product launch invest pipeline focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement pursue discipline capital allocation include business development product pipeline development program manage portfolio basis early discovery latestage development continually evaluate portfolio ensure appropriate balance earlystage latestage program support future growth program phase iii development consider significant program constitute latestage development pipeline development program include investigational compound phase iii development initial indication market product phase iii development additional indication formulation spend program represent approximately annual expense individual investigational compound market product represent expense year latestage development program potentially impact revenue earning year expect latestage development program market follow recent significant development market product latestage pipeline opdivo nivolumab fully human monoclonal antibody bind program death receptor nkt cell investigate anticancer treatment opdivo alliance ono unresectable inoperable metastatic advanced melanoma december company announce food drug administration fda approve opdivo treatment unresectable metastatic melanoma disease progression follow yervoy ipilimumab braf mutation positive braf inhibitor indication approve accelerate approval base tumor response rate durability response continue approval indication contingent verification description clinical benefit confirmatory trial november company announce result checkmate phase iii randomize double blind study compare opdivo chemotherapy dacarbazine dtic patient treatment nave braf wildtype advanced melanoma study meet primary endpoint overall survival median reach opdivo versus month dtic oneyear survival rate opdivo versus dtic decrease risk death patient treat opdivo hazard ratio death survival advantage observe opdivotreated patient pdl positive pdl negative patient september company announce result checkmate phase iii randomize control openlabel study opdivo versus investigator choice chemotherapy icc patient advanced melanoma previously treat yervoy base plan interim analysis coprimary endpoint objective response rate opdivo arm icc reference arm patient month follow september european medicine agency ema validate review marketing authorization application maa opdivo advanced melanoma application grant accelerate assessment emas committee medicinal product human use chmp june company announce randomize blind comparative phase iii study evaluate opdivo versus dacarbazine patient previously untreate braf wildtype advanced melanoma checkmate stop early analysis conduct independent datum monitor committee dmc show evidence superior patient receive opdivo compare control arm patient trial unblinde allow cross opdivo june company announce follow result phase doserange trial evaluate safety activity combination regimen opdivo yervoy give concurrently sequentially patient advance melanoma study additional year follow cohort receive concurrent combination regimen opdivo mgkg plus yervoy mgkg oneyear rate twoyear rate dose ongoing phase phase iii melanoma trial checkmate new safety signal report concurrent combination cohort additional follow company announce update survival datum advanced melanoma cohort expand phase doserange study opdivo administer single agent study result show sustained activity heavily pretreate patient population define threeyear survival rate respectively dose cohort nonsmall cell lung cancer january company announce openlabel randomize phase iii study evaluate opdivo versus docetaxel previously treat patient advance squamous cell nonsmall cell lung cancer nsclc stop early assessment conduct independent dmc conclude study meet endpoint demonstrate superior patient receive opdivo compare control arm company share datum time indicate survival advantage antipd immune checkpoint inhibitor lung cancer health authority october company announce result checkmate phase singlearm openlabel study opdivo administer single agent patient advance squamous cell nsclc progress prior systemic treatment receive prior therapy approximately month minimum follow objective response rate studys primary endpoint assess independent review committee irc recist criterion median duration response reach estimate oneyear survival rate median overall survival mos months september ema validate review maa opdivo advance squamous cell nsclc complete regulatory submission immune checkpoint inhibitor tumor type company announce result phaseb study evaluate safety efficacy opdivo single agent patient advance squamous cell nsclc previously treat study phase study evaluate opdivo single agent chemotherapynave patient checkmate study twoyear survival rate dose previouslytreate patient receive opdivo single agent high patient receive mgkg dose checkmate overall response rate pdl positive tumor pdl negative tumor chemotherapynave patient receive opdivo single agent type treatmentrelate adverse event saes checkmate consistent opdivo trial patient experience grade treatmentrelate saes checkmate multiarm study evaluate opdivo monotherapy combination agent april company meet fda result study evaluate opdivo thirdline squamous cell nsclc initiate roll submission indication base study company complete rolling submission december indication december company announce result cohort patient ongoing phase trial checkmate evaluate opdivo patient relapse refractory hematological malignancy result show high level response patient relapse refractory classical hodgkin lymphoma overall response rate stable disease company announce fda grant opdivo breakthrough therapy designation treatment patient failure autologous stem cell transplant brentuximab company announce result phase phase study opdivo patient advance metastatic renal cell carcinoma phase checkmate doserange trial overall response rate opdivo single agent range oneyear survival rate range patient receive prior antiangiogenic treatment phase checkmate trial overall response rate investigational combination regimen opdivo yervoy range week progression free survival rate range previously treat treatmentnave patient hepatitis portfolio daklinza daclatasvir dcv nsa replication complex inhibitor sunvepra asunaprevir asv protease inhibitor beclabuvir bcv nsb nonnucleoside polymerase inhibitor development february fda notify company intention rescind breakthrough therapy designation certain genotype hepatitis regimen relate daclatasvir investigational bms therapy impact current submissionresubmission timetable new drug application daclatasvir combination antiviral agent treatment hepatitis november company announce fda issue complete response letter crl new drug application nda dcv combination agent treatment hepatitis virus hcv initial dcv nda submit fda focus use combination asv give withdrawal asv bms october fda request additional datum dcv combination antiviral agent treatment hcv bms discussion fda scope data november company announce result unity trial program investigate week regimen alloral dcvtrio regimen fix dose combination dcv asv bcv dcvtrio broad range patient genotype hcv primary endpoint study percentage patient achieve cure define hcv rnalloq tdtnd posttreatment week treatmentnave treatmentexperience patient unity study evaluate cirrhotic patient week regimen dcvtrio show sustained virologic response week treatment svr treatmentnave treatmentexperience cirrhotic patient ribavirin rbv treatmentnave treatmentexperience cirrhotic patient rbv november company announce result landmark ally trial investigate ribavirinfree week regimen dcv combination sofosbuvir sof genotype hcv patient population emerge difficult treat result study show sustained virologic response week treatment svr treatmentnave treatmentexperience patient sof product gilead sciences inc gilead october company announce pursue fda approval dual regimen dcv asv treatment hcv genotype patient withdraw nda asunaprevir company continue pursue fda approval dcv currently investigate globally multiple treatment regimen hcv patient high unmet need august company announce european commission approve daklinza use combination medicinal product genotype treatment chronic hcv infection adult daklinza combination sof alloral interferonfree regiman provide cure rate clinical trial include patient advance liver disease genotype previously fail treatment protease inhibitor daklinza nsa complex inhibitor approve available use combination medicinal product provide short treatment duration week compare week treatment interferon ribavirinbase regimen july company announce japanese ministry health labor welfare approve daklinza sunvepra new hcv treatment lead cure patient japan currently treatment option daklinza sunvepra dual regimen japan alloral interferon ribavirinfree treatment regimen patient genotype chronic hcv infection include compensate cirrhosis indication daklinza sunvepra japan patient ineligible intolerant interferonbase therapy patient fail respond interferonbase therapy elotuzumab humanized monoclonal antibody investigate anticancer treatment elotuzumab alliance abbvie inc abbvie company abbvie announce fda grant elotuzumab breakthrough therapy designation use combination lenalidomide dexamethasone treatment multiple myeloma patient receive prior therapy designation base finding randomize phase openlabel study evaluate dose level elotuzumab combination lenalidomide lowdose dexamethasone previouslytreate patient include mgkg dose study phase iii trial reyataz atazanavir sulfate franchise protease inhibitor treatment human immunodeficiency virus hiv include reyataz include combination therapy evotaz atazanavir cobicistat evotaz alliance gilead january company announce fda approve evotaz tablet treatment hiv infection adult oncedaily single tablet drug regiman combine reyataz tybost sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate product sell joint venture gilead october company announce successfully resolve outstanding patent litigation relate efavirenz active ingredient contain sustiva atripla loss exclusivity efavirenz expect occur december yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma june company announce result phase iii randomize double blind study demonstrate yervoy mgkg significantly improve recurrencefree survival rfs length time recurrence death versus placebo patient stage melanoma high risk recurrence follow complete surgical resection adjuvant set reduction risk recurrence death observe year estimate patient treat yervoy free disease recurrence compare estimate patient placebo median rfs months yervoy versus month placebo median followup year orencia abatacept fusion protein indicate adult patient moderate severe active rheumatoid arthritis indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis november company announce result new subanalyse phase iiib avert assess early rheumatoid arthritis treatment trial investigate use orencia plus methotrexate mtx biologic mtxnave citrullinate protein ccppositive early moderate severe patient firstline therapy orencia combination mtx result patient early achieve significantly high rate stringent measure remission include percent patient achieve booleandefine remission percent patient achieve cdai sdai define remission month versus patient mtx percent percent percent respectively measure june company announce release new datum phase iiib avert trial show orencia combination mtx achieve significantly high rate dasdefine remission month treatment standard care agent mtx biologic mtxnave patient early active eliquis apixaban oral factor inhibitor target stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorder eliquis alliance pfizer november company pfizer portola pharmaceuticals announce result phase annexaa andexanet alfa novel antidote anticoagulant effect fxa inhibitor apixaban studies andexanet alfa produce rapid nearly complete reversal approximately percent value anticoagulant effect eliquis healthy volunteer age august company pfizer announce result prespecifie secondary analysis eliquis phase amplifyext trial apixaban initial management pulmonary embolism deep vein thrombosis firstline therapyextende treatment analysis evaluate clinical demographic predictor allcause hospitalization patient vte include treatment deep vein thrombosis dvt pulmonary embolism result analysis demonstrate month extend treatment vte eliquis significantly reduce risk hospitalization versus placebo august company pfizer announce fda approve supplemental new drug application snda eliquis treatment dvt reduction risk recurrent dvt follow initial therapy july company pfizer announce approve eliquis treatment dvt adult july company pfizer announce patient enrol phase clinical trial call emanate assess effectiveness safety eliquis patient nvaf undergo cardioversion march company pfizer announce result prespecifie subanalysis phase iii aristotle trial assess effect blood pressure control outcome study show result stroke risk reduction eliquis versus warfarin consistent overall aristotle study result demonstrate eliquis reduce stroke systemic embolism cause few major bleed event reduce allcause mortality compare warfarin regardless blood pressure control result show poor blood pressure control associate substantially high risk stroke systemic embolism independent eliquis warfarin treatment march company pfizer announce fda approve snda eliquis prophylaxis deep vein thrombosis lead patient undergo hip knee replacement surgery february company pfizer announce result prespecifie subanalysis phase iii aristotle trial relation patient age aristotle design evaluate efficacy safety eliquis compare warfarin reduce risk stroke systemic embolism patient nvaf subanalysis find consistent result age group reduce risk stroke systemic embolism reduce risk allcause death few bleed event eliquis versus warfarin owe high risk old age age old absolute benefit patient nvaf great eliquis old population result operation total revenue composition change revenue follow year end december total revenue analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization change excess single country outside contribute total revenue period present general business seasonal change revenue attribute volume result diabetes business divestiture february partially offset increase demand eliquis yervoy sprycel change revenue attribute volume result exclusivity loss plavix avaproavalide march partially offset increase demand sprycel yervoy amylinrelate diabetes product revenue follow completion acquisition august change revenue attribute price result high average net selling price abilify aripiprazole key product change revenue attribute price result reduction share abilify revenue impact offset high average net selling price abilify key product key product discussion total revenue key product change europe revenues attribute volume result expiration commercialization rights abilify june diabete business divestiture february loss exclusivity sustiva november partially offset increase demand eliquis yervoy orencia launch daklinza certain country change europe revenues attribute volume result increase demand key product particularly yervoy sprycel orencia amylinrelate product revenue follow transition nonus operation second quarter partially offset restructure sanofi agreement item financial statementsnote alliance discussion revenue period continue negatively impact fiscal challenge european country healthcare payer include government agency reduce expect continue reduce healthcare cost action directly indirectly impose additional price reduction measure include mandatory discount rebate restrictive measure change europe revenues attribute price result reduction atripla revenue sharing average net selling price change rest world revenue attribute volume result increase demand key product particularly eliquis yervoy sprycel launch daklinza sunvepra japan partially offset diabetes business divestiture change rest world revenue attribute volume result growth key product partially offset restructure sanofi agreement generic competition mature brand period impact unfavorable foreign exchange primarily japan revenue increase period high royalty mature brand overthecounter product alliance diabete product supply sale certain alliance revenue expect decline approximately million continue decline expiration relate royalty alliance agreement item financial statementsnote alliance discussion alliance recognize revenue net grosstonet adjustment describe critical accounting policy share certain abilify atripla revenue reflect net grosstonet adjustment alliance revenue present grosstonet adjustment table share abilify atripla grosstonet adjustment approximately billion billion billion change grossto net adjustment impact additional rebate discount require healthcare reform reduction share abilify revenue activity end reserve balance significant category grosstonet adjustment follow manage healthcare chargeback rebate related government cash contract medicaid sale dollar million program discount discount rebate return adjustment total balance january provision relate sale current period prior period return payment assetsrelate liability heldforsale impact foreign currency translation balance december provision relate sale current period prior period return payment impact foreign currency translation balance december reconciliation gross product sale net product sale significant category grosstonet adjustment follow year end december dollar millions gross product sale grosstonet adjustment chargeback related government program cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet adjustment net product sale grosstonet adjustment rate primarily function change revenue mix contractual legislative discount rebate grosstonet adjustment increase decrease chargeback relate government program cash discount decrease result low plavix sale follow loss exclusivity manage healthcare rebate contract discount decrease follow diabetes business divestiture february partially offset high eliquis sale manage healthcare rebate contract discount increase primarily higher amylinrelate sale medicaid rebate increase incremental discount price increase take excess inflation high program participation rate high provision reversal relate sale prior period medicaid rebates decrease low plavix sale high provision reversal relate sale prior period sale return decrease additional reserve establish follow plavix avaproavalide loss exclusivity sale return reserve plavix avaproavalide million million december respectively determine consider factor include estimate inventory level distribution channel accordance company policy product eligible return month prior month product expiration adjustment require future result actual return expect occur adjustment increase primarily high government rebate nonus market product revenue change attributable year end december change foreign exchange dollar million virology baraclude entecavir nonus hepatitis franchise daclatasvir asunaprevir nonus reyataz atazanavir sulfate nonus sustiva efavirenz franchise nonus oncology erbitux cetuximab nonus opdivo nivolumab nonus sprycel dasatinib nonus yervoy ipilimumab nonus neuroscience abilify aripiprazole nonus immunoscience orencia abatacept nonus cardiovascular eliquis apixaban nonus diabetes alliance nonus mature product nonus change excess baraclude oral antiviral agent treatment chronic hepatitis revenue decrease launch generic entecavir teva pharmaceutical industries ltd september revenue increase high average net selling price demand international revenue increase high demand hepatitis franchise daklinza nsa replication complex inhibitor sunvepra protease inhibitor daklinza launch germany august certain country september daklinza sunvepra dual regimen launch japan september reyataz protease inhibitor treatment hiv revenue decrease period low demand result competitor product international revenue decrease time government purchase certain country low demand result competitor product international revenue increase high demand time government purchase certain country period impact unfavorable foreign exchange sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla product sell alliance gilead revenue increase period high average net selling price partially offset low demand international revenue decrease sustiva loss exclusivity europe november negatively impact demand average net selling price atripla revenue sharing erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use treatment patient certain type metastatic colorectal cancer squamous cell carcinoma head neck erbitux alliance lilly revenue remain flat period opdivo fully human monoclonal antibody bind nkt cell investigate anticancer treatment opdivo alliance ono opdivo launch december japan september treatment unresectable metastatic melanoma sprycel oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate sprycel alliance otsuka pharmaceutical ltd otsuka revenue increase period primarily high demand international revenue increase period primarily high demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase period high demand revenue favorably impact recognition million revenue previously defer international revenue increase period high demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder alliance otsuka revenue increase primarily high average net selling price partially offset reduction share abilify revenue revenue decrease reduction contractual share revenue partially offset high average net selling price commercialization right abilify expire april expect loss product exclusivity result significant decline abilify revenue international revenue decrease primarily expiration commercialization rights june otsuka principal end customer sale certain market international revenue increase primarily high demand orencia fusion protein indicate adult patient moderate severe active indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis revenue increase period primarily high average net selling price high demand subcutaneous formulation international revenue increase period primarily high demand subcutaneous formulation partially offset unfavorable foreign exchange eliquis oral factor inhibitor target stroke prevention nonvalvular atrial fibrillation prevention treatment vte disorder eliquis alliance pfizer international revenue continue increase follow launch major market reduction risk stroke systemic embolism patient nvaf treatment vte diabetes alliance include bydureon byetta farxiga onglyzakombiglyze myalept symlin alliance astrazeneca revenue decrease diabetes business divestiture february revenue increase amylin acquisition august high demand average net selling price onglyzakombiglyze item financial statementsnote alliance discussion mature product include product include lose exclusivity major market overthecounter brand royalty relate revenue revenue decrease period continued generic erosion certain product include plavix avaproavalide lose exclusivity result low revenue billion international revenue remain relatively flat continue generic erosion product offset high revenue attribute certain alliance international revenue impact change attribute restructure sanofi agreement avaproavalide plavix item financial statementsnote alliance discussion revenue expect significantly decline reduction approximately million related expiration certain royalty alliance agreement continue decline mature product estimate endus demand pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate reyataz month inventory hand internationally september compare month inventory hand june level inventory exceed month hand primarily government purchasing pattern brazil efferalgan analgesic product sell principally europe month inventory hand internationally september june level inventory hand primarily order pattern pharmacist france generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense change excess cost product sell cost product sell include material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost settlement foreign currency forward contract hedge forecast intercompany inventory purchase transaction essentially cost manage global manufacturing supply organization cost product include royalty profit sharing attribute license product alliance amortization acquire develop technology cost business combination milestone payment occur regulatory approval cost product sell vary period result product mix particularly result royalty profit sharing expense connection alliance price inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility certain cost denominate foreign currency cost product sell percentage total revenue cost product sell decrease primarily diabetes business divestiture billion partially offset high eliquis profit sharing pfizer accelerate depreciation certain manufacturing facility cost product sell remain relatively flat high profit sharing expense high net amortization cost follow amylin acquisition offset low royalty follow loss exclusivity plavix avaproavalide low impairment charge impairment charge million recognize include million relate continued competitive pricing pressure reduction undiscounte project cash flow carrying value develop technology intangible asset remain million impairment charge relate abandonment manufacturing facility result outsource manufacturing process marketing sell administrative marketing selling administrative expense include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization organization global corporate organization finance legal information technology human resource certain expense share alliance partner base contractual agreement marketing sell administrative expense remain relatively flat increase salesrelated activity support eliquis yervoy opdivo hepatitis franchise high variable employee compensation additional brand prescription drug fee offset low expense follow diabetes business divestiture million july irs issue final rule regulation brand prescription drug fee annual nontaxdeductible fee payable federal government affordable care act base allocation company market share brand prescription drug sell certain government program prior year final rule accelerate bms industry participant expense recognition criterion fee obligation year fee pay year market share allocate fee determine result additional year expense recognize quarter include million marketing selling administrative expense million expense final rule regulation change time annual fee pay marketing selling administrative expense decrease accelerate vest amylin stock option restrict stock unit million lower brand prescription drug fee reduction sale relate activity certain product coincide respective lifecycle partially offset high spending support launch new key product additional spending follow amylin acquisition advertising product promotion advertising product promotion expense include medium sample direct consumer program advertise product promotion expense decrease follow diabetes business divestiture advertising product promotion expense increase newly launch product research development research development expense include salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost research development expense include cost discovery research preclinical development early lateclinical development drug formulation clinical trial medical support market product proportionate allocation enterprisewide cost facility information technology employee stock compensation cost appropriate cost upfront licensing fee relate payment achievement regulatory contractual milestone include certain expense share alliance partner base contractual agreement expense attribute development activity manage global research development organization approximately billion billion billion remainder attribute preclinical research activity expense vary period number reason include time upfront milestone licensing payment research development expense increase million iprd impairment charge include million peginterferon lambda high variable employee compensation clinical development cost million charge acquisition ipierian upfront contingent milestone payment million item financial statement note acquisition note goodwill intangible asset information research development expense decrease prior year charge include million iprd impairment charge million accelerate vest amylin stock option restrict stock unit million upfront milestone licensing payment partially offset additional cost follow amylin acquisition high clinical grant spending impairment charge bms intangible asset billion impairment charge recognize development bm inx compound acquire acquisition inhibitex treat hcv discontinued interest patient safety item financial statement note goodwill intangible asset information intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment critical accounting policy discussion incomeexpense year end december dollar million interest expense investment income provision restructure litigation chargesrecoverie equity net income affiliate outlicense intangible asset impairment gain sale product line business asset alliance licensing income pension curtailment settlement special termination benefit incomeexpense provision restructure primarily attributable employee termination benefit result workforce reduction manufacturing sell administrative research development personnel geographic region additional charge approximately million related specialty care transformation initiative expect item financial statementsnote restructure discussion litigation chargesrecoverie include million share apotex damage award concern plavix equity net income affiliate primarily related international partnership sanofi europe asia decrease period result restructure sanofi agreement continues negatively impact generic competition plavix europe asia outlicense intangible asset impairment charge relate certain asset acquire medarex zymogenetics inc acquisition result unfavorable clinical trial result andor abandonment program gain sale product line business asset result primarily diabete business divestiture item financial statementsnote alliance details alliance licensing income include royalty transitional service fee amortization defer income attribute development agreement result diabete business divestiture decrease plavix sale result low development royalty owe sanofi royalty receive sanofi europe asia present revenue begin result restructure sanofi agreement item financial statementsnote alliance discussion pension settlement charge million recognize follow purchase group annuity contract prudential december additional pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan charge include acceleration portion unrecognize actuarial loss similar charge occur future item financial statementsnote pension postretirement postemployment liability detail income taxis dollar million earning income taxis provision forbenefit income taxis effective taxbenefit rate historically effective income tax rate low statutory rate decision indefinitely reinvest earning certain manufacturing operation ireland puerto rico favorable tax rate ireland puerto rico grant schedule expire prior increase effective tax rate result unfavorable earning mix high low tax jurisdiction retroactive reinstatement credit legislation additional tax reserve transfer pricing matter partially offset high tax benefit attribute specify item minimal income taxis attribute diabetes business divestiture gain capital loss deduction sale amylin share tax basis difference result primarily allocate goodwill amylin defer taxis tax benefit attribute research development charge result acquisition ipierian change effective tax rate result million tax benefit attribute capital loss deduction result tax insolvency inhibitex impact deduction reduce effective tax rate percentage point change result low discrete tax benefit attribute intangible asset impairment charge million impairment charge bms high charge contingent tax matter offset favorable earning mix high plavix sale retroactive reinstatement credit legislation item financial statementsnote income taxis detail noncontrolle interest item financial statementsnote alliance discussion plavix avaproavalide partnership sanofi territory cover america decrease noncontrolle interest result exclusivity loss plavix avaproavalide march summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning attributable noncontrolle interest nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item significant andor unusual nature evaluate individual basis similar charge gain item recognize prior period reasonably possible reoccur future period nongaap information intend portray result baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar millions accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell stock compensation accelerate vest amylin award additional year brand prescription drug fee process standardization implementation cost marketing sell administrative stock compensation accelerate vest amylin award upfront milestone licensing payment iprd impairment research development impairment charge bms intangible asset provision restructure gain sale product line business asset pension curtailment settlement special termination benefit acquisition alliance relate itemsa litigation chargesrecoverie loss debt redemption outlicense intangible asset impairment upfront milestone licensing receipt incomeexpense increase pretax income income tax item specify tax chargebenefitbc income taxis increase net earning include million additional year brand prescription drug fee quarter specify tax charge relate transfer pricing matter specify tax benefit relate capital loss deduction reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms gaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation gaap net earning attributable bms gaap specify item net earning attributable bms nongaap earning attributable unvested restricted share net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net cashdebt position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm borrowing longterm debt net cashdebt position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction attributable earning expected indefinitely reinveste offshore cash repatriation subject restriction certain jurisdiction subject withholding additional income taxis believe exist cash cash equivalent marketable security cash generate operation sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment work capital dividend billion billion dividend decision quarterly basis board director capital expenditure approximately million past year expect increase approximately billion high spending expect result expand biologic manufacturing capability facilityrelate activity example planning construct new largescale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio complete february sell astrazeneca substantially diabete business comprise alliance result billion cash flow include royalty item financial statementsnote alliance discussion redeem note entirety outstanding principal note million management periodically evaluate potential opportunity repurchase certain debt security terminate certain interest rate swap contract prior maturity commercial paper borrowing outstanding december marketable security portfolio subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard item financial statement note financial instrument fair value measurement separate billion fiveyear revolve credit facility maintain syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december additional regulation pass future reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer ability collect outstanding receivable direct customer currently believe economic condition material impact liquidity cash flow financial flexibility exposure certain european governmentbacke entity high risk default governmentbacke entity monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio addition entity specific factor exposure reduce factor certain receivables include receivables italy portugal spain million million million factoring receivables japan million million million factoring agreement allow recourse event uncollectibility retain interest underlie asset sell continue manage operate cash flow focus work capital item directly affect change sale volume receivables inventory account payable dollar million december december net trade receivables inventory account payable total credit rating moodys investor service longterm shortterm credit rating prime respectively longterm credit outlook negative standard poor longterm shortterm credit rating respectively longterm credit outlook stable fitch longterm shortterm credit rating respectively revise longterm credit outlook negative stable december credit rating consider investment grade longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee pension contribution tax payment ordinary course business million decrease cash provide operating activity primarily attributable low upfront contingent alliance proceed approximately million reckitt alliance proceed million additional net work capital requirement million partially offset time cash collection payment ordinary course business include item low pension contribution restructure annual bonus payment billion decrease cash provide operating activity primarily attributable low upfront contingent alliance proceed approximately billion amylin alliance proceed billion low operating cash flow attribute plavix avaproavalide revenue reduction follow loss exclusivity approximately million investing activity cash requirement invest activity include cash business acquisition manufacturing facilityrelate capital expenditure purchase marketable security maturity great day reduce proceed business divestiture sale maturity marketable security billion decrease cash investing activity primarily attributable proceed billion allocate diabetes business divestiture partially offset high net purchase marketable security approximately billion cash acquire ipierian million billion decrease cash investing activity primarily attributable cash acquire amylin billion inhibitex billion partially offset high net proceed sale purchase maturity marketable security approximately billion financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing billion increase cash financing activity primarily attributable low net borrowing longterm debt transaction billion million repayment million net borrowing low proceed stock option exercise million million include excess tax benefit partially offset low cash repurchase common stock million billion decrease cash financing activity primarily attributable low cash repurchase common stock billion million billion high net borrowing longterm debt transaction billion million net borrowing million net repayment include debt assume amylin acquisition high proceed stock option exercise million million include excess tax benefit contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb longterm liability total include estimate future interest payment periodic cash settlement derivative include shortterm uncertain tax benefit uncertainty timing resolution addition commit aggregate billion potential future research development milestone payment party license development program include earlystage milestone million milestone achieve phase iii clinical trial latestage milestone billion milestone achieve post phase iii clinical trial payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation item financial statementsnote alliance information alliance discussion contractual obligation item financial statementsnote income taxis note financial instrument fair value measurement note pension postretirement postemployment liability note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain inventory management agreement imas pharmaceutical wholesaler account nearly gross revenue current term ima wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard recently issue accounting standard item financial statementsnote accounting policiesrecently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate accounting policy discuss audit committee board director revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally shipment certain market occur delivery product customer defer approximately million product sell early access program portion recognize revenue subject final price negotiation local government expect conclude revenue reduce grosstonet sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience addition total revenue discussion analysis significant category grosstonet sale adjustment alliance arrangement involve delivery element undelivered element evaluate qualify separate unit accounting consideration fix determinable allocate undelivered element recognize related good service deliver limited consideration contingent future deliverable consideration associate contingent milestone royalty allocate underlie element amount determined payable bms grosstonet adjustment follow category grosstonet adjustment involve significant estimate judgment information obtain external source chargeback related government program business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag cash discount certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag manage healthcare rebate contract discount rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan contract counterpartie hospital group purchasing organization globally rebate require department defense tricare retail pharmacy refund program estimate unpaid unbilled rebate discount present liability million reversal estimate medicare coverage gap discount occur receipt actual invoice medicaid rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability estimate medicaid rebate attributable prior period revenue reduce million million million sale return product typically eligible return month prior month product expiration accordance policy estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loss exclusivity estimate product return present liability reserve establish plavix avaproavalide follow loss exclusivity remain reserve million million december respectively consider relevant factor estimate future retail wholesale inventory work occur loss exclusivity estimate return new product determine consider historical sale return experience similar product product line similar therapeutic category defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product use information external source information external source estimate grosstonet adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citigroup pension discount curve plan plan pension expense determine weightedaverage discount rate present value benefit obligation december pension plan determine discount rate discount rate determine plan pension expense reduce additional expense increase approximately million assumed discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately billion new mortality table mortality improvement scale issue society actuary reflect long life expectancie previous table new table measure pension postretirement obligation begin september result increase obligation approximately million revise mortality rate expect materially impact pension expense future period expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liabilitie business combination divestiture goodwill intangible asset acquire business combination licensing transaction billion represent total asset december accounting transaction business combination divestiture significantly different asset acquisition divestiture example acquire iprd capitalize business combination expense asset acquisition fair value contingent consideration goodwill recognize business combination transaction likewise portion report unit constitute business divest goodwill associate business include carry value business determine gain loss derecognition goodwill occur asset disposition result important determine business asset group asset acquire divest business define asc business combination integrate set input process capable generate output ability provide return investor owner typical input include longlive asset include intangible asset right use longlived asset intellectual property ability obtain access require resource typical process include strategic operational resource management process typically document evident organized workforce consider factor determine business acquire divest stage development commercial product involve example evaluate acquisition ipierian conclude significant process transfer transaction account asset acquisition result million allocate lead investigational compound expense capitalize addition contingent consideration potential regulatory approval milestone million salesbase royalty include purchase price similarly evaluate divestiture diabetes franchise astrazeneca conclude necessary input process transfer consequently transaction account sale business result allocation million goodwill carry value business determine gain sale business combination transaction asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill fair value intangible asset include iprd typically determine income method method starts forecast net cash flow risk adjust estimate probability technical regulatory success iprd adjust present value appropriate discount rate reflect risk associate cash flow stream asset value market participant view different specific bms view valuation process complex require significant input judgment internal external source valuation required finalize oneyear period consider fact evidence available acquisition date complex judgmental matter applicable valuation process summarize unit account intangible asset value single global asset multiple asset jurisdiction indication consider development stage expect level incremental cost obtain additional approval risk associate development time benefit expect derive future expect patent live jurisdiction intention promote asset global brand estimate useful life asset life expect contribute meaningful cash flow determine consider pertinent matter associate asset include expect regulatory approval date unapproved exclusivity period legal regulatory contractual provision effect obsolescence demand competition economic factor include barrier entry probability technical regulatory success ptrs rate ptrs rate determine base industry average consider respective program development stage disease indication adjust specific information datum know acquisition date subsequent clinical result internal external datum obtain alter ptrs rate materially impact estimate fair value intangible asset subsequent period leading impairment charge projection future revenue estimate consider factor initial market opportunity pricing sale trajectory peak sale level competitive environment product evolution future cost expense estimate consider historical market trend market participant synergy timing level additional development cost obtain initial additional regulatory approval maintain enhance product generally assume initial positive cash flow commence shortly receipt expect regulatory approval typically occur number year actual cash flow attribute project likely different assume projection subject multiple factor include trial result regulatory matter materially change ultimate commercial success asset significantly alter cost develop respective asset commercially viable product tax rate expect future income tax effect market participant tax rate recent valuation typically use tax rate applicable state taxis consider jurisdiction intellectual property hold location research manufacturing infrastructure consider earning repatriation likely tax consequence discount rate discount rate select consider risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset item financial statementsnote acquisition specific detail value assign asset acquire liability assume acquisition ipierian amylin inhibitex significant estimate utilize time valuation support fair value lead compound acquisition include estimate phase year discount useful life development project positive dollar million fair value rate utilize year acquisition date ptrs rate utilize cash flow commercialize product bydureon byetta symlin iprd bms inx phase myalept phase iii valuation process require certain multiple element arrangement include determination judgmental complex matter discuss example divestiture diabetes business astrazeneca require determination well estimate selling price element include business supply development agreement include appropriate markup estimate fair value manufacturing facility item financial statementsnote alliance discussion impairment goodwill goodwill billion december goodwill test annually impairment enterprise level assess qualitative factor perform quantitative analysis determine likely fair value exceed carry value example qualitative factor assess current year include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year positive negative influence relevant factor assess individually aggregate result conclude additional quantitative testing require discussion goodwill acquire inprocess research development intangible asset item financial statementsnote accounting policiesgoodwill acquire inprocess research development intangible asset intangible asset include iprd intangible asset billion december include license million develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loss exclusivity pricing pressure adverse regulatory change clinical trial result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market iprd impairment charge likely occur future period recognize charge million include million charge peginterferon lambda phase iii development treatment hcv recognize charge billion include billion charge result discontinue development bms project previously acquire medarex inc inhibitex acquisition result unfavorable clinical trial result additional development cost extend development period decision cease development iprd closely monitor assess period impairment discussion iprd impairment item financial statementsnote goodwill intangible asset addition iprd commercial asset subject impairment example impairment charge million recognize related nonkey product prior acquisition continue competitive pricing pressure operate dynamic market regulatory environment event occur cause expectation change quickly lead potential impairment charge property plant equipment property plant equipment test impairment current fact circumstance warrant review additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use accelerate depreciation relate charge certain manufacturing facility million million million contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion defer tax asset relate federal net operating loss carryforward million federal tax credit carryforward million recognize december net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration assured believe likely defer tax asset realize addition defer tax asset relate federal state capital loss million recognize december carry year carry forward year realization carryforward dependent generate sufficient capital gain prior expiration million valuation allowance establish item december taxis provide undistributed earning foreign subsidiary expect reinveste indefinitely offshore prior mead johnson nutrition company mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know example additional reserve million establish certain transfer pricing matter relate period discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contract manage risk primarily arise certain intercompany purchase transaction designate foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive incomeloss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information item financial statementsnote financial instrument fair value measurement interest rate risk fixedtofloate interest rate swap contract designate fairvalue hedge interest rate risk management strategy contract intend provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million exclude effect counterparty credit risk reduce earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor policy inv institution meet high credit quality standard estimate increase basis point interest rate general decrease fair value debt security portfolio approximately million credit risk material certain european governmentbacke entity high risk default monitor economic factor include credit rating creditdefault swap rate debttogross domestic product ratio entity specific factor historically exposure limited factoring receivables credit exposure europe increase future reduction factor arrangement ongoe sovereign debt crisis credit exposure trade receivables greece portugal italy spain approximately million december approximately governmentbacke entity monitor investment counterpartie objective minimize concentration credit risk investment policy establishe limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fails perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statementsnote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar share million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative advertising product promotion research development impairment charge bms intangible asset incomeexpense total expense earning income taxis provision forbenefit income taxis net earning net earning attributable noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense asset heldforsale total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return income taxis payable dividend payable liability related asset heldforsale total current liability pension postretirement postemployment liability defer income income taxis payable liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization proceed amylin diabetes alliance gain sale business change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity proceed sale maturity marketable security purchase marketable security addition property plant equipment capitalize software business divestiture proceed business acquisition payment net cash provide byused investing activity cash flow financing activity shortterm debt borrowing net proceed issuance longterm debt repayment longterm debt interest rate swap contract termination issuance common stock repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity refer bristol myers squibb bms company intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity use estimate preparation financial statement require use management estimate assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis estimate selling price multiple element arrangement pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty base party sale recognize earn accordance contract term thirdparty sale reliably measurable collectability reasonably assure refer note alliance detail alliance provision time revenue recognition expect sale return discount rebate estimate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation provision recognize reduction revenuewhen new product extension exist line product historical experience product similar therapeutic category revenue defer right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include treasury security government agency security bank deposit time deposit money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include equity net income affiliate incomeexpense equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment length time extent market value cost financial condition investee inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique level fair value input include discount value estimate future cash flow capitalize software eligible cost obtain internal use software significant system project capitalize amortize estimate useful life software insignificant cost obtain software project expense incur business combination business acquire consolidate obtain control acquiree fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill legal audit business valuation business acquisition cost expense incur goodwill acquire inprocess research development intangible asset fair value intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value carry value iprd determine exceed fair value impairment loss recognize difference finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation rationalize manufacture facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incur derivative financial instrument derivative principally management interest rate foreign currency exposure hold trading purpose derivative recognize fair value change fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive incomeloss oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long probable occur gain loss immediately recognize earning nonderivative instrument primarily euro denominate longterm debt designate hedge net investment foreign affiliate effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party research development recognize net reimbursement connection alliance agreement recently issue accounting standard april financial accounting standard board fasb issue amend guidance use presentation discontinue operation entity consolidated financial statement new guidance restrict presentation discontinue operation business circumstance disposal business operation represent strategic shift major effect entity operation financial result guidance effective january adoption prospective basis fasb issue new standard relate revenue recognition require entity recognize revenue expect entitle transfer promise good service customer new standard replace exist revenue recognition standard gaap effective january early adoption permit new standard apply retrospectively prior reporting period present retrospectively cumulative effect change recognize date initial application retain earning company assess potential impact new standard financial reporting select transition method note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible development delivery product market regional commercial organization distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation cardinal health inc amerisourcebergen corporation select geographic area information follow total revenue property plant equipment dollar millions united states europe rest world othera total total revenue include royalty alliancerelate revenue product sell regional commercial organization total revenue key product follow year end december dollar million virology baraclude entecavir hepatitis franchisea reyataz atazanavir sulfate sustiva efavirenz franchiseb oncology erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazolec immunoscience orencia abatacept cardiovascular eliquis apixaban diabetes alliance mature product othere total revenue include daklinza daclatasvir revenue million sunvepra asunaprevir revenue million include alliance revenues million million million include alliance revenues million million million include bydureon exenatide extendedrelease injectable suspension byetta exenatide farxigaxigduo dapagliflozindapagliflozin metformin hydrochloride onglyzakombiglyze saxagliptinsaxagliptin metformin myalept metreleptin symlin pramlintide acetate bms sell diabetes business astrazeneca february include plavix clopidogrel bisulfate revenues million million million additionally include avaproavalide irbesartanirbesartanhydrochlorothiazide revenue million million million note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage refer collaboration alliance partner alliance partner key product abilify sprycel sustiva atripla eliquis erbitux opdivo product comprise diabetes alliance discuss certain mature brand include alliance arrangement payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation amount payable bms alliance partner profit sharing royalty salesbase fee include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense advertising product promotion expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize short contractual term period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present incomeexpense activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca plc astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense equity net income affiliate include incomeexpense payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative advertising product promotion research development incomeexpense noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include defer income classify liability related asset heldforsale million december specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party otsuka bms worldwide commercialization agreement otsuka pharmaceutical ltd otsuka codevelop copromote abilify exclude certain asian country portion agreement amend expire expect loss product exclusivity april agreement expire european union countries june nonus country exclusive right sell abilify agreement expire later april loss exclusivity country party actively participate joint executive governance operate committee otsuka assume responsibility provide funding sale force effort effective january amendment bms responsible funding certain operating expense annual limit bms purchase active pharmaceutical ingredient api otsuka complete manufacture product subsequent sale party customer certain country otsuka assume responsibility provide funding sale force effort effective april bms provide certain service include distribution customer management pharmacovigilence otsuka principal thirdparty product sale principal prior termination june bms principal thirdparty product sale exclusive distributor exclusive right sell abilify alliance revenue recognize bmss share total net sale thirdparty customer territorie bmss contractual share begin january bmss contractual share change percentage total net sale set forth table assessment bms expect annual contractual share complete quarterly reporting period adjust base report abilify net sale year end bms annual contractual share alliance revenue recognize interim period quarter exceed amount contract annual net sale bms share net sale billion billion billion billion billion billion billion billion billion excess billion bmss contractual share thirdparty net sale country alliance revenue recognize abilify ship risk reward ownership transfer thirdparty customer term amendment bm pay otsuka million amortize reduction alliance revenue expect loss exclusivity april unamortized balance include asset otsuka receive royalty base total net sale include cost product sell otsuka responsible expense relate commercialization abilify bms otsuka alliance sprycel ixempra ixabepilone japan party actively participate governance committee bms control decision make party copromote product bms responsible development manufacture product principal endcustomer product sale fee pay otsuka base follow percentage annual net sale sprycel ixempra net sale million million million million million million billion excess billion annual period otsuka contribute million certain commercial operational expense relate oncology product oncology territory cost excess million summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenuesa total revenue payment tofrom otsuka cost product sell oncology fee royalty amortization intangible asset cost product supply cost reimbursement tofrom otsuka recognize cost product sell marketing sell administrative advertising product promotion research development incomeexpense select alliance balance sheet information december dollar million asset extension payment include amortization extension payment reduction alliance revenue million astrazeneca prior diabetes business divestiture discuss bms alliance astrazeneca consist worldwide codevelopment commercialization agreement cover onglyza relate combination product sell name farxiga relate combination product begin august bms acquisition amylin pharmaceuticals inc amylin amylin portfolio product include bydureon byetta symlin myalept certain asset own amylin include manufacturing facility locate west chester ohio coexclusive license right product product underlying agreement grant astrazeneca exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance party actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal endcustomer product sale substantially country alliance agreement right transfer astrazeneca standalone value right sell separately bms party astrazeneca receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting result upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive billion nonrefundable upfront payment astrazeneca consideration enter amylin alliance astrazeneca exercise option equal governance right certain key strategic financial decision amylin alliance pay bms million consideration payment account deferred income amortize base relative fair value predominant element include alliance estimate useful life intangible asset relate bydureon estimate useful life year byetta estimate useful life year symlin estimate life year myalept estimate useful life year amylin manufacture plant estimate useful life year amortization present reduction cost product sell alliance asset acquire shortly commencement alliance astrazeneca entitle share proceed sale asset amortization acquire amylin intangible asset manufacturing plant present cost product sell bms entitle reimbursement capital expenditure relate acquire amylin manufacturing facility bms astrazeneca share certain tax attribute relate amylin alliance prior termination alliance bms receive nonrefundable upfront milestone licensing payment million relate onglyza million relate farxiga amortization onglyza farxiga deferred income include income onglyza farxiga commercial product commencement alliance party share commercialization development expense equally profit loss february bms astrazeneca terminate alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan future purchase bmss manufacturing facility locate mount vernon indiana substantially employee dedicated diabetes business transfer astrazeneca sale business complete jurisdiction bms astrazeneca enter agreement connection sale include supply agreement development agreement transitional service agreement agreement bms obligate supply certain product include active product ingredient onglyza farxiga perform ongoing development activity certain clinical trial program provide transitional service account financial service customer service distribution regulatory development information technology certain administrative service period order facilitate orderly transfer business operation annual cost attribute development agreement expect exceed approximately million consideration transaction include billion payment close contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable royalty payment base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee royalty rate net sale follow onglyza farxiga worldwide net sale million onglyza farxiga worldwide net sale million amylin product net sale stock asset purchase agreement contain multiple element deliver subsequent closing transaction include china diabete business transfer quarter mount vernon indiana manufacturing facility activity development supply agreement element determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method determine well estimate selling price element remain consideration include calculation gain sale diabete business contingent milestone royalty payment similarly allocate underlie element amount determined payable bms amount allocate sale business immediately recognize result operation amount allocate element recognize result operation extent element deliver consideration billion account substantially quarter include royalty million contingent regulatory milestone payment relate approval farxiga japan approximately billion consideration allocate sale business remain million allocate undelivered element describe consideration include million earn royalty include million allocate element deliver gain sale diabete business million include million quarter result primarily transfer china diabete business astrazeneca gain base difference consideration allocate sale business exclude royalty net transaction fee carry value diabete business net asset include million allocation goodwill reversal million net defer tax liability attribute amylin consideration allocate mount vernon indiana manufacturing facility continue defer transfer astrazeneca consideration allocate development supply agreement continue amortize applicable service period amortization defer income attribute development agreement include income sale service consider bmss ongoing major central operation revenue attribute supply agreement include alliance revenue consideration transaction present cash flow purpose base allocation process describe invest activity attribute sale business relate asset operating activity attribute transitional service supply arrangement development agreement summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenue payment tofrom astrazeneca cost product sell profit sharing amortization defer income cost reimbursement tofrom astrazeneca recognize cost product sell marketing sell administrative advertising product promotion research development incomeexpense amortization defer income provision restructure royalty transitional service gain sale business select alliance cash flow information defer income business divestiture proceed select alliance balance sheet information december dollar millions deferred income attribute nonrefundable upfront milestone licensing receiptsa asset transfer astrazeneca service perform astrazeneca include liability relate asset heldforsale december gilead bms gilead sciences inc gilead joint venture canada europe develop commercialize atripla efavirenz emtricitabine tenofovir disoproxil fumarate combine sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint venture consolidate gilead party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada api bulk form party complete finishing atripla joint venture gilead sell distribute atripla principal thirdparty customer sale party long coordinate joint promotional activity alliance revenue recognize atripla include bulk efavirenz component atripla base relative ratio average respective net selling price truvada sustiva alliance revenue defer related alliance receivable recognize combined product sell thirdparty customer europe follow loss exclusivity sustiva effective january percentage atripla net sale europe recognize bms equal difference average net selling price atripla truvada alliance continue europe party terminate arrangement patent expiration occur atripla truvada sustiva agreement terminate gilead launch generic version sustiva bms launch generic version truvada event gilead terminate agreement loss exclusivity sustiva bms receive quarterly royalty payment month follow termination payment month follow termination equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price second year follow termination payment bms reduce respectively atripla net sale multiply price ratio describe bms continue supply sustiva cost plus markup joint venture threeyear period party elect terminate supply arrangement summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer income lilly bms epidermal growth factor receptor egfr commercialization agreement eli lilly company lilly lilly subsidiary imclone development copromotion erbitux canada japan egfr agreement party actively participate joint executive committee operating committee share responsibility research development resource infrastructure respect erbitux lilly manufacture bulk requirement cetuximab facility fill finish perform party bms oversight responsibility bms responsible promotional effort north america lilly right copromote expense bms development copromotion right canada japan bms principal thirdparty customer sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly agreement expire erbitux north america september bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly december bms agree transfer cocommercialization right japan merck kgaa exchange future royalty include income earn march bms lilly terminate arrangement necitumumab imcf right return lilly discover imclone necitumumab fully human monoclonal antibody alliance bms lilly license acquisition cost million associate erbitux alliance agreement amortize summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale alliance revenue total revenue payment tofrom lilly cost product sell distribution fee royalty amortization intangible asset cost product supply cost reimbursement tofrom lilly incomeexpense japan commercialization fee select alliance balance sheet information december dollar million intangible asset nonrefundable upfront milestone licensing payment bms acquire amylin pharmaceuticals inc amylin august note acquisition information amylin previously enter settlement termination agreement lilly alliance global development commercialization byetta bydureon exenatide product party agree transition responsibility product amylin transition operation complete prior acquisition transition nonus operation majority market complete april terminate lilly nonus exclusive right promissory note assume acquisition amylin aggregate billion repay lilly sanofi september bms sanofi restructure term codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico alliance plavix market continue unchanged december term original alliance arrangement describe exchange right transfer sanofi bms receive quarterly royalty january december terminal payment sanofi million end begin royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenues million million development optout royalty income million include incomeexpense development royalty expense sanofi million present cost product sell million present incomeexpense royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate equity net income affiliate include million profit defer prior restructure agreement alliance revenue attribute supply irbesartan api sanofi million million million supply arrangement irbesartan expire prior restructure bmss worldwide alliance sanofi codevelopment cocommercialization avaproavalide plavix operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia territory partnership manage central expense market research development royalty supply finish product individual country bms act operating partner own majority control interest territory cover americas australia consolidated country partnership result territory sanofis share result reflect noncontrolle interest bms recognize net product sale comarkete country outside territory italy irbesartan germany greece spain sanofi act operating partner own majority control interest territory cover europe asia bms ownership interest territory summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi cost product supply cost product sell royalty equity net income affiliate incomeexpense noncontrolle interest pretax select alliance cash flow information distribution tofrom sanofi noncontrolle interest distribution sanofi investment affiliate select alliance balance sheet information december dollar million investment affiliate territory cover europe asiaa noncontrolle interest include alliance receivables follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income cost product sell territory cover europe asia include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately million million million relate receivablespayable attribute cash distribution bms sanofi intercompany balance partnership territory pfizer bms pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement eliquis anticoagulant discover bms pfizer fund development cost depend study company share profit loss equally global basis certain country pfizer commercialize eliquis pay bms compensation base percentage net sale enter agreement coexclusive license right product grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate alliance actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal endcustomer product sale country determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize life relate product bms receive million nonrefundable upfront milestone licensing payment relate eliquis date amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing cost reimbursement tofrom pfizer incomeexpense amortization defer income select alliance cash flow information defer income select alliance balance sheet information december dollar millions defer income reckitt benckiser group bms reckitt benckiser group plc reckitt enter threeyear alliance overthecounterproduct sell primarily mexico brazil net sale product approximately million reckitt receive right sell distribute market product certain responsibility relate regulatory matter cover territory bms receive royalty net sale product exclusively supply certain product reckitt cost plus markup certain limited asset include market authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine base multiple sale plus cost remain inventory hold bms time april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance option exercise substantially employee facility expect transfer reckitt option exercise option exercise asset previously transfer reckitt revert bms option exercise reckitt november case closing expect occur nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability million charge include expense increase fair value option million allocate right transfer reckitt amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenues reckitt alliance alliance revenues select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions defer income medicine company february bms medicine company enter twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleed surgical procedure previously acquire bms connection acquisition zymogenetics inc net product sale recothrom million medicine company receive right sell distribute market recothrom global basis year certain responsibility relate regulatory matter cover territory bm exclusively supply recothrom medicine company cost plus markup receive royalty net sale recothrom certain employee directly attribute business certain asset transfer medicine company start alliance period include biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option acquire business million february note asset heldforsale information nonrefundable upfront proceed million receive bms allocate unit account include right transfer medicine company fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option million december determine level input include accrue expense allocate right transfer medicine company amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue medicines company alliance alliance revenues select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions deferred income valeant october bms pharmaswis whollyowne subsidiary valeant pharmaceuticals international inc valeant enter alliance certain mature brand product europe valeant receive right sell distribute market product europe december certain responsibility relate regulatory matter cover territory bm exclusively supply product valeant cost plus markup bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale valeant exercise option acquire business million january nonrefundable upfront proceed million receive bms allocate unit account include right transfer valeant fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include accrue expense million charge include expense increase fair value option million allocate right transfer valeant amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenue valeant alliance net product sale alliance revenue total revenue select alliance cash flow information defer income change operate asset liability select alliance balance sheet information december dollar millions defer income ono bms ono pharmaceutical ltd ono alliance agreement develop commercialize opdivo antipd human monoclonal antibody investigate anticancer treatment bms exclusive right develop manufacture commercialize opdivo territory worldwide japan south korea taiwan ono responsible development commercialization prior amendment discuss ono entitle receive royalty follow regulatory approval territory exclude country list royalty rate north america applicable territory alliance agreement amend july provide additional collaboration activity japan south korea taiwan pertain opdivo bms compound include ipilimumab lirilumab urelumab bms antilag party right obligation jointly develop commercialize compound bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay party sale partys assign customer summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenue payment tofrom ono cost product sell copromotion fee cost reimbursement tofrom ono recognize research development fstar october bms enter agreement fstar alpha ltd fstar agreement provide bms exclusive option purchase fstar alpha ltd phase ready lead asset target therapy development treatment breast gastric cancer welldefine population herpositive patient bms pay million fstar shareholder option fee certain licensing right include research development expense responsible conducting funding development option exercisable bms discretion expire early day follow obtain proof concept june additional million payable exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payment europe bms obligate provide additional financial support fstar fstar determine business define asc business combination result contingent consideration include purchase price goodwill recognize fstar variable interest entity equity holder lack characteristic control financial interest bms determine primary beneficiary power direct activity significantly directly impact economic performance entity option right describe consolidation noncontrolle interest credit million reflect fair value iprd asset million defer tax liability note acquisition ipierian inc acquisition april bms acquire outstanding share ipierian inc ipierian biotechnology company focus new treatment tauopathie class neurodegenerative disease acquisition provide bms right ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathie consideration include upfront payment million contingent development regulatory milestone payment million future royalty net sale acquire preclinical asset approve commercialize significant ipierian process acquire transaction account asset acquisition ipierian determine business upfront payment allocate ipn million include research development expense remain million allocate defer tax asset net operating loss tax credit carryforward amylin pharmaceuticals inc acquisition august bms acquire outstanding share amylin biopharmaceutical company focus discovery development commercialization innovative medicine treat diabete metabolic disease acquisition cost million include expense bms obtain commercialization right amylin primary commercialize asset bydureon onceweekly diabete treatment byetta daily diabete treatment glucagonlike peptide glp receptor agonist approve certain country improve glycemic control adult type diabete bms obtain commercialization right symlin amylinomimetic approve adjunctive therapy mealtime insulin treat diabete goodwill generate acquisition primarily attribute expansion diabetes franchise iprd attribute metreleptin analog human hormone leptin study develop treatment diabetes andor hypertriglyceridemia pediatric adult patient inherit acquire lipodystrophy estimate useful life cash flow utilize value metreleptin assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result note alliancesastrazeneca discussion sale company diabetes business include amylin astrazeneca comprise global diabetes alliance inhibitex inc acquisition february bms acquire outstanding share inhibitex inc inhibitex clinicalstage biopharmaceutical company focus develop product prevent treat infectious disease acquisition cost million include expense bms obtain inhibitexs lead asset inx oral nucleotide polymerase nsb inhibitor phase development treatment chronic hepatitis virus infection goodwill generate acquisition primarily attribute potential offer portfolio therapy choice hepatitis virus infection provide additional level sustainability bmss virology pipeline iprd primarily attribute inx inx expect effective combination therapy assume market participant inherently maintain franchise synergy attribute maximize cash flow exist virology pipeline asset cash flow utilize value inx include synergy assume initial positive cash flow commence shortly expect receipt regulatory approval subject trial result august company discontinue development inx interest patient safety result company recognize noncash pretax impairment charge billion information discussion impairment charge note goodwill intangible asset total consideration transfer allocation acquisition date fair value asset acquire liability assume amylin inhibitex acquisition follow dollar million identifiable net asset amylin inhibitex cash marketable security inventory property plant equipment develop technology right iprd asset debt obligation liability defer income taxis total identifiable net asset goodwill total consideration transfer cash pay acquisition amylin include payment billion outstanding common stockholder million holder stock option restrict stock unit include million attribute accelerate vest account stock compensation expense result operation cash flow acquire company include consolidated financial statement acquisition date pro forma supplemental financial information provide impact acquisition material operating result year acquisition goodwill iprd intangible asset value acquisition nondeductible tax purpose note asset heldforsale discuss note alliance bms sell diabetes business astrazeneca february previously comprise global alliance diabete business treat single disposal group heldforsale december writedown require fair value business cost sell exceed related carrying value asset heldforsale december relate alliance medicine company valeant allocation goodwill base relative fair value business divest company reporting unit follow table provide asset liability classify heldforsale december december dollar million asset receivables inventory defer income taxis current prepay expense property plant equipment goodwill intangible asset asset asset heldforsale liability shortterm borrowing current portion longterm debt account payable accrue expense defer income current accrue rebate return defer income noncurrent defer income taxis noncurrent liability liabilitie relate asset heldforsale note incomeexpense incomeexpense include year end december dollar million interest expense investment income provision restructure litigation chargesrecoverie equity net income affiliate outlicense intangible asset impairment gain sale product line business asset alliance licensing income pension curtailment settlement special termination benefit incomeexpense note restructuring follow provision restructuring year end december dollar million employee termination benefit exit cost provision restructure restructuring charge include employee termination benefit manufacturing sell administrative research development workforce reduction geographic region approximately restructure action primarily relate specialty care transformation initiative design create simplify organization function geographic market sale force reduction european country follow restructure sanofi otsuka alliance agreement subject local regulation cost recognize completion discussion work council additional cost million expect incur specialty care transformation initiative follow table represent activity employee termination exit cost liability year end december dollar million liability january charge change estimate provision restructure foreign currency translation amylin acquisition liability relate asset heldforsale spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provisionbenefit effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate foreign tax effect certain operation ireland puerto rico switzerland tax effect capital loss federal state foreign contingent tax matter federal research base credit goodwill relate diabete divestiture brand prescription drug fee charge state local taxis net valuation allowance foreign effective tax rate low statutory rate primarily attributable undistributed earning certain foreign subsidiary consider expect indefinitely reinveste offshore taxis provide approximately billion undistributed earning foreign subsidiary december undistribute earning primarily relate operation ireland puerto rico operate favorable tax grant schedule expire prior undistributed earning repatriate future determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide reform tax law relate foreign earning propose adopt increase taxis reduce result operation cash flow divestiture diabete business result million capital loss tax benefit sale amylin share additional reserve million establish certain transfer pricing matter related tax period goodwill allocate diabete business divestiture brand prescription drug fee research development charge acquisition ipierian deductible tax purpose retroactive reinstatement federal research development credit result additional tax credit million tax insolvency inhibitex result million capital loss tax benefit orphan drug credit include federal research base credit period present defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward milestone payment license fee defer income capital loss carryforward federal net operating loss carryforward pension postretirement benefit state net operating loss credit carryforward intercompany profit inventory item federal tax credit carryforward foreign defer tax asset sharebase compensation legal settlement repatriation foreign earning internal transfer intellectual property total defer tax asset valuation allowance net defer tax asset defer tax liability depreciation acquire intangible asset total defer tax liability defer tax asset net recognize asset heldforsale defer income taxis current deferred income taxis noncurrent income taxis payable current liability relate asset heldforsale income taxis payable noncurrent total federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin federal tax credit carryforward expire vary amount begin realization federal tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration capital loss available million carry carryforward expire amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal state capital loss change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition balance end year income tax payment million million million current tax benefit realize result stock relate compensation credit capital excess par value stock million million million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty interest expense penalty expensebenefit accrue interest penalty payable unrecognized tax benefit include current noncurrent foreign income taxis payable interest penalty relate unrecognized tax benefit include income tax expense effective january bms adopt update fasb clarify exist guidance presentation unrecognize tax benefit qualifying tax benefit carryforward exist include unrecognized tax benefit present reduction defer tax asset liability non current defer tax asset income tax liability reduce million adoption bms currently examination number tax authority include limited major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense bms estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms earning attributable unvested restricted share net earning attributable bms common shareholder earning share basic weightedaverage common share outstanding basic contingently convertible debt common stock equivalent incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share dilute antidilutive weightedaverage equivalent share stock incentive plan note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize nonbinde quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument nonbinde quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liability instrument include corporate debt security certificate deposit money market fund foreign currency forward contract interest rate swap contract equity fund fix income fund longterm debt additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment significant unfunded commitment restriction redemption relate equity fix income fund december level derivative instrument value london interbank offer rate libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract credit adjustment volatility significant impact valuation interest rate swap contract result change counterparty credit rating credit default swap spread level unobservable input little market datum available fair value write option sell asset certain business note alliance discussion base option pricing methodology consider revenue profitability projection volatility discount rate potential exercise price assumption fair value contingent consideration relate acquisition estimate utilize model consider probability achieve milestone discount rate financial asset liability measure fair value recur basis summarize december december dollar million level level level total level level level total cash cash equivalent money market security marketable security certificate deposit corporate debt security equity fund fix income fund auction rate security ar derivative asset interest rate swap contract foreign currency forward contract equity investment derivative liability interest rate swap contract foreign currency forward contract write option liability contingent consideration liability follow table summarize activity financial asset utilize level fair value measurement write contingent write contingent option consideration ar option consideration dollar million ar liability liability frsa liability liability fair value january addition new alliance unrealize gain sale change fair value fair value december float rate security availableforsale security follow table summarize availableforsale security gross gross unrealize unrealized gain loss amortize accumulate accumulate dollar million cost oci oci fair value december certificate deposit corporate debt security ars equity investment total december certificate deposit corporate debt security ar total availableforsale security include current marketable security million december million december noncurrent availableforsale corporate debt security mature year december ar equity investment million include asset december fair value option financial asset investment equity fix income fund offset change fair value certain employee retirement benefit include current marketable security investment income result change fair value significant qualifying hedge follow summarize fair value outstanding derivative december december dollar million balance sheet location notional fair value notional fair value derivative designate hedge instrument interest rate swap contract asset interest rate swap contract liabilitie foreign currency forward contract prepay expense foreign currency forward contract asset foreign currency forward contract accrue expense foreign currency forward contract liabilitie cash flow hedge foreign currency forward contract primarily utilize hedge forecast intercompany inventory purchase transaction certain foreign currency contract designate cash flow hedge effective portion change fair value report accumulate oci recognize earning hedge item affect earning net gain expect reclassify cost product sell year notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december fair value foreign currency forward contract attribute japanese yen notional million designate cash flow hedge million include prepay expense december cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present net investment hedge nonus dollar borrowing million million designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange gain loss remeasurement debt recognize foreign currency translation component accumulate oci relate offset long term debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize reduction interest expense remain life debt notional fixedtofloate interest rate swap contract execute million billion notional fixedto float interest rate swap contract terminate million generating proceed million include accrue interest million additional contract terminate connection debt redemption debt obligation shortterm borrowing million million december respectively consist primarily bank overdraft longterm debt current portion longterm debt include december dollar millions principal value euro note note note note euro note note debenture note debenture note note note note debenture mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount total current portion longterm debta longterm debt include liability relate asset heldforsale december fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument float rate convertible senior debenture million redeemable holder par september fundamental change ownership occur callable par time bms debenture current conversion price equal conversion rate share principal subject certain antidilutive adjustment senior unsecured note issue register public offering billion billion interest note pay semiannually note rank equally right payment bmss exist future senior unsecured indebtedness redeemable bms time predetermine redemption price note principal million mature repay substantially billion debt obligation assume acquisition amylin repay include promissory note lilly respect revenue sharing obligation amylin senior note debt redemption debt redemption activity include repayment amylin debt obligation follow dollar million principal carry value redemption price notional interest rate swap contract terminate swap termination proceedspayment total loss interest payment million million million net amount receive interest rate swap contract separate billion fiveyear revolve credit facility maintain syndicate lender facility provide customary term condition financial covenant extendable anniversary date consent lender borrowing outstanding revolve credit facility december financial guarantee provide form standby letter credit performance bond million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivable december dollar million trade receivable allowance net trade receivables alliance partner receivables prepaid refundable income taxis miscellaneous receivables receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization asset heldforsale balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory expect remain onhand year million december million december include asset note property plant equipment december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment property plant equipment relate mount vernon indiana manufacturing facility approximately million december facility expect sell include asset heldforsale period assets available immediate sale present condition note alliance discussion sale diabete business depreciation expense million million million note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year inprocess research development iprd gross intangible asset accumulate amortization total intangible asset goodwill million allocate sale diabete business include million present asset heldforsale december seenote asset heldforsale discussion amortization expense million million million future annual amortization expense intangible asset expect approximately million million million million million million intangible asset impairment charge million billion million iprd impairment charge recognize peginterferon lambda phase iii development treatment hepatitis virus hcv writeoff require assess potential commercial viability asset estimate fair value assessment consider low likelihood file registration certain market complete revise projection revenue expense significant decline prior project revenue result global introduction oral noninterferon product treat patient hcv alternative use product bm announce discontinued development bm know inx nucleotide polymerase nsb inhibitor phase development treatment hcv august decision interest patient safety base rapid thorough ongoing assessment patient phase study voluntarily suspend august bm acquire bms acquisition inhibitex february result termination development program billion pretax impairment charge recognize impairment charge million recognize related continued competitive pricing pressure partial writedown fair value develop technology right relate previously acquire nonkey product note accrue expense december dollar million employee compensation benefit royaltie accrue research development restructure current pension postretirement benefit accrue litigation total accrue expense note sale rebate return accrual reduction trade receivable accrue rebate return liability follow december dollar million chargeback relate government program cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment accrue rebate return note deferred income december dollar million alliance note gain saleleaseback transaction total defer income current portion noncurrent portion alliance include unamortized amount upfront milestone licensing proceed revenue deferral attribute gilead alliance undelivered element diabete business divestiture upfront milestone licensing proceed amortize short contractual right period expect life product defer gain saleleaseback transaction amortize remain lease term relate facility deferral include approximately million invoice product early access program portion recognize revenue subject final price negotiation local government amortization defer income million million million deferred income million include liability relate asset heldforsale december seenote asset heldforsale discussion note equity common stock capital treasury stock excess par value retain noncontrolle dollar share million share par value stock earning share cost interest balance january net earning cash dividend declare stock repurchase program employee stock compensation plan comprehensive income attributable noncontrolle interest distribution balance december net earning cash dividend declare stock repurchase program employee stock compensation plan distribution balance december net earning cash dividend declare employee stock compensation plan debt conversion variable interest entity distribution balance december treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method noncontrolle interest primarily relate plavix avaproavalide partnership sanofi territory cover america net earning attributable noncontrolle interest present net taxis million million million corresponding increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis activity include pretax income distribution relate partnership component comprehensive incomeloss follow dollar million pretax tax tax derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gain realize gainsd availableforsale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial gain amortizationb settlementsc pension postretirement benefit availableforsale security unrealize loss realize gainsd availableforsale security foreign currency translation derivative qualify cash flow hedgesa unrealize gain reclassify net earning derivative qualify cash flow hedge pension postretirement benefit actuarial loss amortizationb settlement curtailmentsc pension postretirement benefit availableforsale security unrealize gain realize gainsd availableforsale security foreign currency translation reclassification net earning derivative qualify effective hedge recognize cost product sell actuarial gainslosse prior service costcredit amortize cost product sell research development marketing sell administrative expense pension settlement curtailment recognize incomeexpense realize gain availableforsale security recognize incomeexpense accumulate balance relate component comprehensive incomeloss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note pension postretirement postemployment liabilitie bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation bms contribute minimum require employee retirement income security act erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security net periodic benefit costcredit define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial gainloss curtailment settlement special termination benefit net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan enter definitive agreement transfer certain pension asset prudential insurance company america prudential settle approximately billion pension obligation bms purchase group annuity contract prudential december irrevocably assume obligation future annuity payment certain bms retiree transaction change monthly pension benefit receive affected retiree survive beneficiary result pretax settlement charge million pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement plan amendment actuarial gainslosses retiree drug subsidy benefit pay exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy benefit pay exchange rate gainslosse fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability fund status recognize accumulate comprehensive loss net actuarial gainslosse prior service credit total accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit creditcost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value fair value plan asset exceed marketrelated value million december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include long term historical return input external advisor individual asset class return forecast develop base market condition example price earning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan amortization net actuarial loss prior service credit expect approximately million periodic benefit cost credit include cost product sell research development marketing sell administrative expense curtailment settlement special termination benefit include expense assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate material impact service interest cost post retirement benefit obligation plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total equity security equity fund fix income fund corporate debt security venture capital limit partnership government mortgage back security treasury agency security shortterm investment fund insurance contract event drive hedge fund state municipal bond real estate cash cash equivalent total plan asset fair value investment valuation policy investment class follow level input utilize quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input instrument include equity security equity fund real estate fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input include observable price similar instrument quote price identical similar instrument market active observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund event drive hedge fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end significant unfunded commitment restriction redemption relate investment value nav december corporate debt security government mortgage back security treasury agency security state municipal bond classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available venture capital limit partnership classify level fair value hierarchy invest underlying security market value determine pricing model discount cash flow methodology similar technique significant unobservable input valuation methodology include discount rate earn interest taxis depreciation amortization ebitda multiple revenue multiple significant change input result significantly lower high fair value measurement insurance contract interest carry contract value approximate estimate fair value base fair value underlie investment insurance company insurance contract hold certain foreign pension plan follow summarize activity financial asset utilize level fair value measurement venture capital limited insurance dollar million partnership contract total fair value january purchase sale settlement net realize gainslosse unrealize gainslosse fair value december purchase sale settlement net realize gainslosse unrealize gainslosse fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage venture capital limited partnership typically value month lag late available information bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect approximately million estimate annual future benefit payment include lump sum payment range million million year aggregate billion subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan million note employee stock benefit plan shareholder approve stock award incentive plan plan replace stock incentive plan share common stock reserve issuance pursuant stock plan option conversion prefer stock million december share available grant active plan million december share issue treasury stock share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right common stock stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date compensation expense recognize vest period stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment base company performance share ultimately issue award grant prior calculate base actual performance compare earning target performance criterion establish beginning year year performance cycle share ultimately issue award grant base actual performance compare earning target performance criterion establish subsequent adjustment company threeyear total shareholder return relative peer group company vest occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period acceleration unvested stock option restrict stock unit connection acquisition amylin result stockbase compensation expense forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million stock option restrict stock unit market share unit performance share unit amylin stock option restrict stock unit note total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share thousand outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value option award vest year stock option restrict stock unit market share unit performance share unit total intrinsic value stock option exercise year fair value award approximate close trading price bms common stock grant date fair value market share unit consider payout formula probability satisfy market condition follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding exercisable number weightedaverage weightedaverage outstanding exercisable remain contractual exercise price aggregate range exercise price thousand life year share intrinsic value aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note lease annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense million million million sublease income material period present note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property baraclude august teva file anda manufacture market generic version baraclude company receive paragraph certification letter teva challenge orange bookliste patent baraclude patent patent cover entecavir molecule september company file patent infringement lawsuit district court district delaware delaware district court teva infringement february delaware district court rule company invalidated patent company appeal delaware district court decision june court appeal federal circuit federal court appeal deny company appeal july company file petition banc rehear entire federal court appeal deny october january company file petition writ certiorari supreme court request court hear appeal federal court appeal decision september teva receive final approval fda generic version entecavir launch product experience rapid significant negative impact net product sale baraclude begin fourth quarter net product sale baraclude million baraclude south korea daewoong pharmaceutical ltd hanmi pharmaceuticals ltd initiate separate invalidity action korean intellectual property office korean patent patent patent expire october korean equivalent patent composition matter patent january korean intellectual property tribunal rule patent valid remain risk generic company continue challenge validity patent andor launch generic version baraclude prior october net product sale baraclude south korea million plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex australian government intervene matter seek damage allege loss experience period injunction place company apotex settle apotex case case dismiss australian government claim pende possible time predict outcome australian government claim impact company plavix canada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid june sanofi file defense impeachment action file suit apotex infringement patent trial complete june december federal court canada issue decision patent invalid july federal court appeal reverse federal court canada decision uphold validity patent case remand federal court canada consider damage owe company apotex infringement patent september apotex seek leave appeal decision federal court appeal supreme court canada supreme court canada schedule hear case november company apotex settle case dismiss conclude matter general commercial litigation remain apotex matter relate plavix previously disclose january apotex file lawsuit florida state court broward county allege breach contract relate propose settlement agreement apotex relate pende plavix patent litigation trial hold march jury verdict deliver favor company apotex appeal decision company apotex settle apotex withdraw appeal conclude matter pricing sale promotional practice litigation investigation abilify federal subpoena january company receive subpoena united states attorney office sdny request information relate thing sale marketing abilify possible time assess outcome matter potential impact company abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute company enter tolling agreement state possible time reasonably assess outcome investigation awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende state court pennsylvania wisconsin begin august company defendant trial commonwealth court pennsylvania commonwealth court bring commonwealth pennsylvania september jury issue verdict company find company liable fraudulent negligent misrepresentation commonwealth court judge issue decision pennsylvania consumer protection claim jury find company liable million enjoin company contribute provision inflate awps company appeal decision pennsylvania supreme court oral argument take place june pennsylvania supreme court vacate commonwealth judge decision remand matter commonwealth court january commonwealth court enter judgment favor company possible commonwealth pennsylvania appeal decision qui tam litigation march company serve unseal qui tam complaint file sale representative california superior court county los angeles california department insurance elect intervene lawsuit complaint allege company pay kickbacks california providers pharmacy violation california insurance frauds prevention act cal in code possible time reasonably assess outcome lawsuit impact company plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix currently claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california illinois new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court possible time reasonably assess outcome lawsuit potential impact company reglan company number defendant numerous lawsuit behalf approximately plaintiff include injury plaintiff claim personal injury allegedly sustain reglan brand generic drug metoclopramide product indicate gastroesophageal reflux certain gastrointestinal disorder claim spouse andor beneficiary company generic subsidiary apothecon inc distribute metoclopramide tablet manufacture party possible time reasonably assess outcome lawsuit resolution pende lawsuit expect material impact company byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court company agree principle resolve claim majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego recently establish multidistrict litigation large contingent case pende coordinated proceed california superior court los angeles amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca possible reasonably predict outcome lawsuit claim proceed potential impact company environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party new brunswick facilityenvironmental personal injury lawsuit lawsuit file company new jersey superior court behalf current resident new brunswick new jersey live live adjacent company new brunswick facility complaint allege personal injury result environmental contamination new brunswick facility historical operation site claim medical monitoring portion complaint assert claim allege property damage october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose october additional case file new jersey superior court remove company united states district court district new jersey accordingly excess case state federal court action june company plaintiff agree settlement finalize december conclude matter north brunswick township board education previously disclose october company contact counsel represent north brunswick board education boe site waste material squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean avoid litigation central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit interim funding payment december november party commence mediation late effort successful party move bind allocation process party expect conduct fact expert discovery follow formal evidentiary hearing write argument addition september township boe file suit party allege contribute waste material site litigation settle party company currently believe responsible additional amount interim payment total million transmit additional possible loss expect material proceeding sec germany investigation october sec inform company begin formal inquiry activity certain company german pharmaceutical subsidiary employee andor agent sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act fcpa company cooperate sec fcpa investigation march company receive subpoena sec issue connection investigation fcpa primarily relate sale marketing practice country company cooperate sec department justice investigation matter particular company investigate certain sale marketing practice china possible time assess outcome matter potential impact company note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debt equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earningsloss attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset include current portion longterm debt follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda additional year brand prescription drug fee process standardization implementation cost marketing sell administrative upfront milestone payment iprd impairment research development provision restructure gain sale product line business asset pension curtailment settlement special termination benefit acquisition alliance relate itemsb litigation chargesrecoverie loss debt redemption outlicense intangible asset impairment upfront milestone licensing receipt incomeexpense increasedecrease pretax income income tax item specify tax chargec income taxis increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost include million additional year brand prescription drug fee quarter specify tax charge relate transfer pricing matter second fourth dollar million quarter quarter quarter quarter year accelerate depreciation asset impairment shutdown cost amortization acquire amylin intangible asset amortization amylin alliance proceed amortization amylin inventory adjustment cost product sell marketing selling administrativea research developmentb provision restructure pension settlement acquisition alliance relate item litigation recovery upfront milestone licensing receipt incomeexpense increase pretax income income tax item increase net earning specify item marketing sell administrative process standardization implementation cost specify item research development upfront milestone licensing payment report independent register public accounting firm board director shareholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting item information report independent register public accounting firm board director shareholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion consolidated financial statement deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item item